<SEC-DOCUMENT>0001193125-23-301183.txt : 20231221
<SEC-HEADER>0001193125-23-301183.hdr.sgml : 20231221
<ACCEPTANCE-DATETIME>20231221160550
ACCESSION NUMBER:		0001193125-23-301183
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20231221
DATE AS OF CHANGE:		20231221

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Annexon, Inc.
		CENTRAL INDEX KEY:			0001528115
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				275414423
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-258863
		FILM NUMBER:		231505351

	BUSINESS ADDRESS:	
		STREET 1:		1400 SIERRA POINT PARKWAY
		STREET 2:		BLDG C, SUITE 200
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005
		BUSINESS PHONE:		(650)-822-5500

	MAIL ADDRESS:	
		STREET 1:		1400 SIERRA POINT PARKWAY
		STREET 2:		BLDG C, SUITE 200
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d446052d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(5)<BR>Registration No. 333-258863 </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Prospectus supplement </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">(To
prospectus dated May&nbsp;3, 2022) </P> <P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g446052g01g01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>25,035,000 Shares of Common stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants to Purchase 18,379,861 Shares of Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Pursuant to this prospectus supplement and the accompanying base prospectus, we are offering 25,035,000&nbsp;shares of our common stock, par value $0.001 per share, or,
in lieu of common stock to certain investors that so choose, <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase 18,379,861&nbsp;shares of our common stock. The purchase price of each
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant will equal the price per share at which shares of our common stock are being sold to the public in this offering, minus $0.001, multiplied by the number of shares subject to the warrant, and
the exercise price of each <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant will equal $0.001 per share. The public offering price of each share of common stock is $2.880. We are also offering the shares of our common stock that are
issuable from time to time upon exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">There is no established public trading market for the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants, and we do not expect a market to develop. We do not intend to apply for listing of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants on The Nasdaq Global Select Market or any
securities exchange or nationally recognized trading system. Without an active trading market, the liquidity of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants will be limited. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Our common stock is listed on the Nasdaq Global Select Market under the symbol &#147;ANNX.&#148; On December&nbsp;19, 2023, the last reported sale price of our common
stock on the Nasdaq Global Select Market was $2.83 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Investing in our common stock involves a high degree of risk. Please read &#147;<A HREF="#supptoc446052_5">Risk
 factors</A>&#148; beginning on page <FONT STYLE="white-space:nowrap">S-7</FONT> of this prospectus supplement, in the accompanying prospectus and in the documents incorporated by reference into this prospectus supplement and the accompanying base
prospectus. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined
if this prospectus supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PER&nbsp;SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PER</B><br><B><FONT STYLE="white-space:nowrap">PRE-FUNDED</FONT></B><br><B>WARRANT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Public Offering Price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.879</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">125,016,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Underwriting&nbsp;discounts&nbsp;and&nbsp;commissions<SUP STYLE="font-size:75%; vertical-align:top">&nbsp;(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,500,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.7072</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.7063</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">117,515,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="11%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><SUP STYLE="font-size:75%; vertical-align:top">See &#147;Underwriting&#148; for a description of the compensation payable to the underwriters. </SUP></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The underwriters expect to deliver the shares of common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchasers on or about
December&nbsp;26, 2023. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><I>Joint book-running managers </I></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:16pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="50%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:16pt">
<TD VALIGN="top"><B>Jefferies</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>TD&nbsp;Cowen</B></TD></TR>
</TABLE> <P STYLE="margin-top:20pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">December&nbsp;20, 2023 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Prospectus supplement</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#supptoc446052_1">About this prospectus supplement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#supptoc446052_2">Market, industry and other data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#supptoc446052_3">Prospectus supplement summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#supptoc446052_4">The offering</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#supptoc446052_5">Risk factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#supptoc446052_6">Special note regarding forward-looking statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-9</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#supptoc446052_7">Use of proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-11</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#supptoc446052_8">Dividend policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-12</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#supptoc446052_10">Material U.S. federal income tax consequences to <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holders of our common stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-13</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#supptoc446052_11">Description of securities we are offering</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-19</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#supptoc446052_12">Underwriting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-21</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#supptoc446052_13">Legal matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-31</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#supptoc446052_14">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-31</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#supptoc446052_15">Where you can find more information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-31</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#supptoc446052_16">Incorporation of certain information by reference</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-31</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Prospectus </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toca446052_1">About this Prospectus</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toca446052_2">Where You Can Find More Information; Incorporation by Reference</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toca446052_3">The Company</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toca446052_4">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toca446052_5">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toca446052_6">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toca446052_7">Description of Debt Securities</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toca446052_8">Description of Warrants</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toca446052_9">Description of Units</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toca446052_10">Global Securities</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toca446052_11">Plan of Distribution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toca446052_12">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toca446052_13">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="supptoc446052_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus supplement and the accompanying prospectus are part of a registration statement that we have filed with the Securities and Exchange Commission, or the
SEC, utilizing a &#147;shelf&#148; registration process. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We provide information to you about this offering of our securities in two separate documents that are
bound together: (1)&nbsp;this prospectus supplement, which describes the specific details regarding this offering of common stock, and (2)&nbsp;the accompanying base prospectus, which provides general information, some of which may not apply to this
offering. Generally, when we refer to this &#147;prospectus,&#148; we are referring to both documents combined. If information in this prospectus supplement is inconsistent with the accompanying prospectus, you should rely on this prospectus
supplement. However, if any statement in one of these documents is inconsistent with a statement in another document having a later date&#151;for example, a document incorporated by reference in this prospectus supplement&#151;the statement in the
document having the later date modifies or supersedes the earlier statement as our business, financial condition, results of operations and prospects may have changed since the earlier dates. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have not, and the underwriters have not, authorized anyone to provide any information other than that contained in or incorporated by reference in this prospectus
supplement, the accompanying prospectus and any free writing prospectus prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any
other information that others may give you. We are not, and the underwriters are not, making an offer to sell or soliciting an offer to buy our securities in any jurisdiction where an offer or solicitation is not authorized or in which the person
making that offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make an offer or solicitation. You should assume that the information appearing in this prospectus supplement, the accompanying prospectus, the
documents incorporated by reference herein and therein, and in any free writing prospectus that we may authorize for use in connection with this offering, is accurate only as of the date of those respective documents. Our business, financial
condition, results of operations and prospects may have changed since those dates. You should read this prospectus supplement, the accompanying prospectus, the documents incorporated by reference into this prospectus, and any free writing prospectus
that we may authorize for use in connection with this offering, in their entirety before making an investment decision. You should also read and consider the information in the documents to which we have referred you in the sections of this
prospectus supplement titled &#147;Where you can find more information&#148; and &#147;Incorporation of certain information by reference.&#148; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are offering to
sell, and seeking offers to buy, securities only in jurisdictions where offers and sales are permitted. The distribution of this prospectus supplement and the offering of the securities in certain jurisdictions may be restricted by law. Persons
outside the United States who come into possession of this prospectus supplement must inform themselves about, and observe any restrictions relating to, the offering of the securities and the distribution of this prospectus supplement outside the
United States. This prospectus supplement does not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus supplement by any person in any jurisdiction in
which it is unlawful for such person to make such an offer or solicitation. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">When we refer to &#147;Annexon,&#148; &#147;ANNX,&#148; &#147;we,&#148;
&#147;our,&#148; &#147;us&#148; and the &#147;Company&#148; in this prospectus supplement, we mean Annexon, Inc. and its consolidated subsidiary, unless otherwise specified. When we refer to &#147;you,&#148; we mean the potential holders of our
securities. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">&#147;Annexon,&#148; &#147;Annexon, Inc.,&#148; the Annexon logo and other trade names, trademarks or service marks of Annexon are the property of
Annexon, Inc. This prospectus supplement also contains references to our trademarks and to trademarks belonging to other entities. Trade names, trademarks and service marks of other companies appearing in this prospectus supplement are the property
of their respective holders. We do not intend our use or display of other companies&#146; trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies. Solely for convenience, the trade names
and trademarks may be referred to without the <SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and <SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> symbols, but such references should not be construed as any indicator that their
respective owners will not assert their rights thereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="supptoc446052_2"></A><A NAME="supptoc446052_2"></A>MARKET, INDUSTRY AND OTHER DATA </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus supplement, including the information incorporated by reference herein, contains estimates, projections and other information concerning our industry,
our business and the markets for certain drugs, including data regarding the estimated size of those markets, their projected growth rates and the incidence of certain medical conditions. Information that is based on estimates, forecasts,
projections or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this
industry, business, market and other data from reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources. In some cases, we do not expressly refer
to the sources from which this data is derived. In that regard, when we refer to one or more sources of this type of data in any paragraph, you should assume that other data of this type appearing in the same paragraph is derived from the same
sources, unless otherwise expressly stated or the context otherwise requires. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="supptoc446052_3"></A>PROSPECTUS SUPPLEMENT SUMMARY </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>This summary provides a general overview of selected information and does not contain all of the information you should consider before buying our securities.
Therefore, you should read the entire prospectus supplement, accompanying prospectus and any free writing prospectus that we have authorized for use in connection with this offering carefully, including the information incorporated by reference
herein and therein, before deciding to invest in our securities. Investors should carefully consider the information set forth under the section titled &#147;Risk factors&#148; beginning on page <FONT STYLE="white-space:nowrap">S-9</FONT> of this
prospectus supplement and in the documents incorporated by reference into this prospectus supplement, including our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and our Quarterly Reports on Form
<FONT STYLE="white-space:nowrap">10-Q.</FONT> </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a
clinical-stage biopharmaceutical company pioneering a new class of complement medicines for people living with devasting inflammatory-related diseases. The classical complement pathway is a core component to the body&#146;s immune system that
activates a powerful inflammatory cascade. We believe that by stopping the classical complement pathway at its start by targeting C1q, the initiating molecule of the classical complement pathway, our approach may have the potential to provide more
complete protection against complement-mediated disorders of the body, brain and eye. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Using our proprietary platform, we are identifying and characterizing the
role of the classical complement pathway in three therapeutic areas&#151;autoimmune, neurodegeneration and ophthalmology. In so doing, we are advancing a pipeline of product candidates designed to block the early classical cascade and all downstream
pathway components and their tissue-damaging functions. Our goal is to suppress excessive or aberrant classical complement activity that contributes to chronic inflammation and tissue damage to slow or even halt disease progression, while preserving
the beneficial immune functions of the lectin and alternative complement pathways involved in the clearance of pathogens and damaged cells. We have demonstrated robust target engagement in the body, brain and eye, and clinical proof of concept in
multiple diseases, and have focused our resources on development of three priority programs: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Guillain-Barr&eacute; Syndrome, or GBS</B>: We are advancing our lead candidate, ANX005, an investigational,
full-length monoclonal antibody, or mAb, formulated for intravenous administration in a pivotal Phase 3 clinical trial for the potential treatment of patients with GBS. GBS is a rare antibody-mediated autoimmune disease with no U.S. Food and Drug
Administration, or FDA, approved therapies, and for which we believe maximum suppression of C1q and the classical cascade early in the disease process may act to rapidly prevent nerve damage and irreversible neurological disability. We demonstrated
clinical <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> in a prior placebo-controlled trial and have achieved target enrollment of approximately 225 patients in our ongoing Phase 3 GBS trial, with
data anticipated in the first half of 2024. ANX005 has been granted orphan drug designation for the treatment of GBS from both the FDA and the EMA. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Geographic Atrophy, or GA</B>: We are evaluating ANX007, an antigen-binding fragment, or Fab, formulated for
intravitreal administration, for the potential treatment of patients with GA, the leading cause of blindness resulting from damaged and dying retinal cells. ANX007 is designed to block C1q locally in the eye to provide more complete protection
against excess classical complement activity, a key driver of disease. In a randomized, multi-center, double-masked, sham-controlled Phase 2 ARCHER clinical trial, ANX007 demonstrated a trend on the anatomical-based primary endpoint, but showed
consistent protection against vision loss in a broad population of patients with GA. Specifically, topline data reported in May 2023 and presented at the American Society of Retina Specialists (ASRS) Annual Meeting in July 2023 showed that ANX007
provided statistically significant, time and dose-dependent protection from vision loss in patients with GA, measured by best corrected visual acuity (BCVA)
<FONT STYLE="font-family:Times New Roman">&#8805;</FONT><FONT STYLE="white-space:nowrap">15-letter</FONT> loss, the widely accepted and clinically meaningful functional endpoint. In October 2023, we announced that the EMA granted Priority Medicine
(PRIME) designation to ANX007 for the treatment of GA secondary to <FONT STYLE="white-space:nowrap">age-related</FONT> macular degeneration. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
In December 2023, we announced a global registrational program for ANX007, expected to include a single global sham-controlled ARCHER II clinical trial and a second ARROW <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> clinical trial using SYFOVRE<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> as an injection comparator. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>ANX1502 for Autoimmune Indications</B>: ANX1502 is a novel oral small molecule inhibitor of the classical complement
pathway, which we believe is <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-kind.</FONT></FONT> We completed a Phase 1 <FONT STYLE="white-space:nowrap">single-ascending</FONT> dose, or SAD, and multiple-ascending dose, or
MAD, clinical trial in healthy volunteers designed to evaluate the safety, tolerability, pharmacokinetics, or PK, and pharmacodynamics, or PD, of ANX1502. In December 2023, we announced results from the Phase 1 trial. ANX1502 was generally
well-tolerated, achieved target serum levels and demonstrated PK and PD measures that we believe support advancement into a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> study in patients with cold
agglutinin disease, or CAD, in 2024. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to our priority programs, we continue to be encouraged by multiple &#145;next wave&#146;
programs, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Huntington&#146;s Disease, or HD: </B>We are evaluating ANX005 for the potential treatment of patients with HD, a
slowly progressing, inherited and fatal neurodegenerative disease in which we believe C1q triggers synapse loss and neuroinflammation. We completed a Phase 2 clinical trial in patients with manifest HD in 2022, in which ANX005 demonstrated positive
efficacy results and was generally well-tolerated. We are assessing the initiation of a planned late-stage trial in HD in 2024 as the company prioritizes near-term pivotal development activities for GBS, GA and ANX1502. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Lupus Nephritis, or LN</B>: We completed a Phase 1b signal-finding trial of ANX009, a C1q Fab formulated for
subcutaneous delivery, using a precision medicine approach for patients with LN who have high baseline complement activity. LN is an autoimmune disease for which pathogenic <FONT STYLE="white-space:nowrap">anti-C1q</FONT> antibodies (PACAs) enhance
activity and uniquely amplify kidney inflammation and damage. Initial results were presented at the American Society of Nephrology&#146;s Kidney Week 2023 conference, which showed subcutaneous ANX009 was well tolerated and demonstrated plasma C1q
target engagement and complement inhibition. Importantly, inhibition of C1q rapidly increased free/circulating PACA levels (consistent with decreased deposition in the kidney) and inhibited all downstream markers of complement consumption and
activation (C4, as well as C3 and C5). These results indicate that C1q and the classical pathway are key drivers of complement activation in LN, independent of the alternative and lectin pathways, and that PACAs are a component of the classical
complement activation pathway. Consistent with the short duration of this signal-finding study (3 weeks), changes in urinary protein excretion were not observed as anticipated. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Amyotrophic Lateral Sclerosis, or ALS</B>: We are evaluating ANX005 in a Phase 2a signal-finding clinical trial in
patients with ALS, a fatal neurodegenerative disorder characterized by C1q activation driving inflammation and neurodegeneration. Preliminary Phase 2a data as of December&nbsp;6, 2022 from the first eight patients in the trial showed that treatment
with ANX005 resulted in a reduction in neurofilament light, or NfL, a neurodegenerative disease biomarker, and slowed disease progression as measured by reductions in revised ALS functional rating scores during the initial <FONT
STYLE="white-space:nowrap">12-week</FONT> <FONT STYLE="white-space:nowrap">on-treatment</FONT> period, followed by an increase in disease progression in the <FONT STYLE="white-space:nowrap">off-treatment</FONT> period. We expect to report full <FONT
STYLE="white-space:nowrap">on-treatment</FONT> data from the Phase 2a clinical trial by early 2024. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Beyond our clinical-stage assets, leveraging
the learnings from our initial trials and our expertise in the role of C1q and the classical complement pathway, we are evaluating additional orphan and large market indications that are driven by aberrant or excess classical complement activation.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Corporate information </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We were incorporated under the laws of the State
of Delaware on March&nbsp;3, 2011. Our principal executive offices are located at 1400 Sierra Point Parkway, Bldg C, Suite 200, Brisbane, California 94005, and our telephone number is (650) <FONT STYLE="white-space:nowrap">822-5500.</FONT> Our
corporate website address is www.annexonbio.com. Information contained on, or accessible through, our website shall not be deemed incorporated into and is not a part of this prospectus supplement or the registration statement of which it forms a
part. We have included our website in this prospectus supplement solely as an inactive textual reference. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="supptoc446052_4"></A>THE OFFERING </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL"><B>Common stock offered by us </B></P></TD>
<TD>25,035,000&nbsp;shares of common stock. </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Pre-funded</FONT> warrants offered by us </B></P></TD>
<TD>We are also offering, in lieu of common stock to certain investors that so choose, <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase 18,379,861&nbsp;shares of our common stock. The purchase price of each <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrant equals the price per share at which the shares of our common stock are being sold to the public in this offering, minus $0.001 which is the exercise price of each
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant per share. Each <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant will be exercisable at any time after the date of issuance of such
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant, subject to an ownership limitation. See &#147;Description of Securities We Are <FONT STYLE="white-space:nowrap">Offering&#151;Pre-Funded</FONT> Warrants&#148; on page <FONT
STYLE="white-space:nowrap">S-19</FONT> of this prospectus supplement. This prospectus supplement also relates to the offering of the shares of our common stock issuable upon exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrants. </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL"><B>Common stock to be outstanding immediately after this offering </B></P></TD>
<TD>78,338,098&nbsp;shares, assuming no exercise of any <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants issued in this offering. </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL"><B>Use of proceeds </B></P></TD>
<TD>We estimate that the net proceeds to us from this offering will be approximately $117.1&nbsp;million, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. </TD></TR></TABLE>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We currently intend to use the net proceeds from this offering, together with our existing cash, cash equivalents and marketable securities, to advance the global registrational program for ANX007 in geographic atrophy,
the development of our pipeline of other product candidates and for working capital and other general corporate purposes. See &#147;Use of proceeds&#148; on page <FONT STYLE="white-space:nowrap">S-13</FONT> of this prospectus supplement.
</TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL"><B>Risk factors </B></P></TD>
<TD>Investing in our common stock involves significant risks. You should read the &#147;Risk factors&#148; section of this prospectus supplement and in the documents incorporated by reference in this prospectus supplement and the accompanying
prospectus for a discussion of factors to consider before deciding to purchase shares of our common stock. </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL"><B>Nasdaq Global Select Market symbol </B></P></TD>
<TD>&#147;ANNX.&#148; We do not intend to apply for listing of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants on the Nasdaq Global Select Market or any securities exchange or nationally recognized trading system. There is no public
trading market for the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, and we do not expect a market to develop. Without a trading market, the liquidity of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants will be
extremely limited. See &#147;Description of We Are <FONT STYLE="white-space:nowrap">Offering&#151;Pre-Funded</FONT> Warrants&#148; for additional information. </TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The number of shares of common stock to be outstanding immediately after this offering is based on 53,238,985 shares
of common stock outstanding as of September&nbsp;30, 2023, and excludes: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">9,335,202 shares of our common stock issuable upon the exercise of stock options outstanding as of September&nbsp;30,
2023, with a weighted-average exercise price of $10.45 per share; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">183,600 shares of our common stock issuable upon the exercise of stock options outstanding that we granted after
September&nbsp;30, 2023 and through the date of this prospectus supplement, with a weighted-average exercise price of $2.37 per share; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">533,917 shares of our common stock issuable upon the vesting of restricted stock units outstanding as of
September&nbsp;30, 2023; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">1,743,618 shares of our common stock reserved for future issuance under our 2020 Incentive Award Plan as of
September&nbsp;30, 2023, as well as any automatic increases in the number of shares of our common stock reserved for future issuance under this plan; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">1,401,331 shares of our common stock reserved for future issuance under our Employee Stock Purchase Plan as of
September&nbsp;30, 2023, as well as any automatic increases in the number of shares of our common stock reserved for future issuance under this plan; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">870,400 shares of our common stock reserved for future issuance under our 2022 Employment Inducement Award Plan as of
September&nbsp;30, 2023; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">up to 22,113,649 shares of common stock issuable upon the exercise of <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrants outstanding as of September&nbsp;30, 2023, with an exercise price of $0.001 per share; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">up to 8,427,508 shares of common stock issuable upon the exercise of common warrants outstanding as of September&nbsp;30,
2023, with an exercise price of $5.806875 per share. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On August&nbsp;16, 2021, we established an &#147;at the market offering&#148; program, or
ATM Program, with Cowen and Company, LLC, or TD Cowen, as sales agent, pursuant to which the Company may issue and sell shares of our common stock for an aggregate maximum offering price of $100.0&nbsp;million from time to time, in such amounts as
we may determine, subject to certain limitations contained therein and under applicable securities laws. As of the date of this prospectus supplement, we have sold 2,646,458 shares of our common stock to an entity related to one of our directors at
a price of $6.80 per share for aggregate gross proceeds of approximately $18.0&nbsp;million. Net proceeds were approximately $17.5&nbsp;million after commissions of approximately $0.5&nbsp;million were paid to TD Cowen. We have agreed not to make
any sales under the ATM Program until the expiration or waiver of the <FONT STYLE="white-space:nowrap">60-day</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> period applicable to us and described in the section titled
&#147;Underwriting.&#148; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Unless otherwise indicated, all information in this prospectus supplement assumes no exercise or settlement, as applicable, of the
outstanding options, restricted stock units, <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants and common warrants described above, and no exercise of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants offered and sold in this
offering. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="supptoc446052_5"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Our business involves significant risks, some of which are described below. You should carefully review the risks and uncertainties described below and under the
section titled &#147;Risk factors&#148; contained in our Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K</FONT> for the year ended December&nbsp;31, 2022, as updated by our Quarterly Reports on Form
<FONT STYLE="white-space:nowrap">10-Q</FONT> and subsequent filings under the Exchange Act, each of which is incorporated by reference in this prospectus supplement in their entirety, together with other information in this prospectus supplement and
the accompanying prospectus, and the information and documents incorporated by reference in this prospectus supplement and the accompanying prospectus, and any free writing prospectus that we have authorized for use in connection with this offering
before you make a decision to invest in our securities. If any of the following risks actually occur, it could harm our business, operating results, financial condition and future prospects. In such event, the market price of our common stock or
value of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants could decline and you could lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also
impair our business operations. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks relating to this offering </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our management team may invest or spend the proceeds of this offering in ways with which you may not agree or in ways which may not yield a significant return.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our management will have broad discretion over the use of proceeds from this offering. We currently intend to use the net proceeds from this offering,
together with our existing cash, cash equivalents and marketable securities, to advance the clinical development of ANX007 through Phase 3, the development of our pipeline of other product candidates and for working capital and other general
corporate purposes. Our management will have considerable discretion in the application of the net proceeds, and you will not have the opportunity, as part of your investment decision, to assess whether the proceeds are being used appropriately. The
net proceeds may be used for corporate purposes that do not increase our operating results or enhance the value of our common stock. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>There is no public
market for the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants being offered in this offering. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There is no established public trading market
for the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants being offered in this offering, and we do not expect a market to develop. In addition, we do not intend to apply to list these <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrants on any securities exchange or nationally recognized trading system, including The Nasdaq Global Select Market. Without an active market, the liquidity of these <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants will be limited. See
&#147;Description of Securities We Are <FONT STYLE="white-space:nowrap">Offering&#151;Pre-Funded</FONT> Warrants.&#148; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We will not receive any meaningful
amount of additional funds upon the exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant has an exercise price of $0.001 per share of common stock. Each <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant will be exercisable until it is fully exercised by means of payment
of this nominal purchase price. Accordingly, we will not receive any meaningful additional funds upon the exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Holders of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants purchased in this offering will have no rights as common stockholders until such holders
exercise their <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants and acquire our common stock. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Until holders of the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants acquire shares of our common stock upon exercise of such <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, the holders will have no rights with respect to the shares of our common
stock underlying such <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, such as voting rights or the rights to receive dividends. Upon exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, the holders will be
entitled to exercise the rights of a common stockholder only as to matters for which the record date occurs after the exercise. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Significant holders or
beneficial holders of our common stock may not be permitted to exercise <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants that they hold. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Holders
of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants will not be entitled to exercise any portion of any <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant which, upon giving effect to such exercise, would cause the aggregate
number of shares of our common stock beneficially owned by the holder (together with its affiliates) to exceed a specified percentage of the number of shares of our common stock outstanding immediately after giving effect to the exercise, as such
percentage ownership is determined in accordance with the terms of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. As a result, you may not be able to exercise your <FONT STYLE="white-space:nowrap">pre-funded</FONT>
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
warrants for shares of our common stock at a time when it would be financially beneficial for you to do so. In such circumstance you could seek to sell your
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to realize value, but you may be unable to do so in the absence of an established trading market for the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>You may experience future dilution as a result of future equity offerings. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In order to raise additional capital, we expect to in the future offer additional shares of our common stock or other securities convertible into or exchangeable for
our common stock. We cannot assure you that we will be able to sell shares or other securities in any other offering at a price per share that is equal to or greater than the price per share or pre-funded warrant paid by investors in this offering,
and investors purchasing shares or other securities in the future could have rights superior to existing stockholders. The price per share at which we sell additional shares of our common stock or other securities convertible into or exchangeable
for our common stock in future transactions may be higher or lower than the price per share in this offering. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The sale of our common stock in this offering
and any future sales of our common stock, including any shares issuable upon exercise of our <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, or the perception that such sales could occur, may depress our stock price and our ability to
raise funds in new stock offerings. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may from time to time issue additional shares of common stock at a discount from the current trading price of our
common stock. As a result, our stockholders would experience immediate dilution upon the purchase of any shares of our common stock sold at such discount. In addition, as opportunities present themselves, we may enter into financing or similar
arrangements in the future, including the issuance of debt securities, preferred stock or common stock. Sales of shares of our common stock in this offering, including any shares issuable upon exercise of any
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants issued in this offering, or the perception that such sales could occur, may lower the market price of our common stock and may make it more difficult for us to sell equity securities or
equity-related securities in the future at a time and price that our management deems acceptable, or at all. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>An active trading market for our common stock
may not be sustained following this offering. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Although our common stock is listed on The Nasdaq Global Select Market, an active trading market for our
shares may not be sustained. If an active market for our common stock does not continue, it may be difficult for you to sell your shares, including shares you may purchase in this offering, without depressing the market price for the shares or sell
your shares at all. Any inactive trading market for our common stock may also impair our ability to raise capital to continue to fund our operations by selling shares and may impair our ability to acquire other companies or technologies by using our
shares as consideration. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="supptoc446052_6"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus supplement, the accompany prospectus, including the documents incorporated by reference herein and therein, and any free writing prospectus that we
have authorized for use in connection with this offering contain forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Exchange Act, based upon current expectations that involve risks and
uncertainties. In some cases, you can identify forward-looking statements by terminology such as &#147;anticipate,&#148; &#147;believe,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148;
&#147;may,&#148; &#147;plan,&#148; &#147;potentially,&#148; &#147;predict,&#148; &#147;should,&#148; &#147;will&#148; or the negative of these terms or other similar expressions. These forward-looking statements include, but are not limited to,
statements about: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our expectations regarding the potential market size and size of the potential patient populations for our product
candidates and any future product candidates, if approved for commercial use; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our clinical and regulatory development plans; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our expectations with regard to the results of our clinical studies, preclinical studies and research and development
programs, including the timing and availability of data from such studies; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the timing of commencement of future nonclinical studies and clinical trials and research and development programs;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our ability to acquire, discover, develop and advance product candidates into, and successfully complete, clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our intentions and our ability to establish collaborations and/or partnerships; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the timing or likelihood of regulatory filings and approvals for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our commercialization, marketing and manufacturing capabilities and expectations; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our intentions with respect to the commercialization of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the pricing and reimbursement of our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the potential effects of <FONT STYLE="white-space:nowrap">COVID-19</FONT> on our preclinical and clinical programs and
business; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the implementation of our business model and strategic plans for our business and product candidates, including additional
indications which we may pursue; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the scope of protection we are able to establish and maintain for intellectual property rights covering our product
candidates, including the projected terms of patent protection; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">estimates of our expenses, future revenue, capital requirements, our needs for additional financing and our ability to
obtain additional capital; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our intended use of proceeds from this offering and our existing cash, cash equivalents and marketable securities;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the potential future sales of our common stock under our ATM program; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our future financial or operating performance; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">developments and projections relating to our competitors and our industry, including competing products.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These forward-looking statements are based on management&#146;s current expectations, estimates, forecasts and projections about our business and
the industry in which we operate and management&#146;s beliefs and assumptions and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our
control. As a result, any or all of our forward-looking statements in this prospectus supplement may turn out to be inaccurate and you should not rely upon forward-looking statements as predictions of future events. Factors that may cause actual
results to differ materially from current expectations include, among other things, those listed under the section titled &#147;Risk factors&#148; in this prospectus supplement, the accompanying prospectus, and the documents incorporated by
reference herein and therein. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time and it is not possible for our management to predict all risks, nor can we assess the impact of all factors
on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Potential investors are urged to consider these factors
carefully in evaluating the forward-looking statements. These forward-looking statements speak only as of the date of this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
prospectus supplement. Except as required by law, we assume no obligation to update or revise these <FONT STYLE="white-space:nowrap">forward-looking</FONT> statements for any reason, even if new
information becomes available in the future. You should, however, review the factors and risks we describe in the reports we will file from time to time with the SEC after the date of this prospectus supplement. See &#147;Where you can find more
information&#148; and &#147;Incorporation of certain information by reference.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="supptoc446052_7"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We estimate that the net proceeds to us from this offering will be approximately $117.1&nbsp;million, after deducting the underwriting discounts and commissions and
estimated offering expenses payable by us. These estimates exclude the proceeds, if any, from the exercise of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants sold in this offering. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We currently intend to use the net proceeds from this offering, together with our existing cash, cash equivalents and marketable securities, to advance the global
registrational program for ANX007 in geographic atrophy, the development of our pipeline of other product candidates and for working capital and other general corporate purposes. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The amounts and timing of our actual expenditures will depend on numerous factors, including our development and commercialization efforts with respect to our product
candidates, as well as the amount of cash used in our operations. We therefore cannot estimate with certainty the amount of net proceeds to be used for the purposes described above. Based upon our current operating plan, we believe that the net
proceeds of our offering, together with our existing cash and cash equivalents and short-term investments will enable us to fund our operating expenses and capital expenditure requirements into the second quarter of 2026. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pending the uses described above, we plan to invest the net proceeds from this offering in short-term, <FONT STYLE="white-space:nowrap">investment-grade,</FONT>
interest-bearing securities. We cannot predict whether the proceeds invested will yield a favorable return. Our management will have broad discretion in the use of the net proceeds from this offering, and investors will be relying on the judgment of
our management regarding the application of the net proceeds. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="supptoc446052_8"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have never declared or paid, and do not anticipate declaring or paying in the foreseeable future, any cash dividends on our capital stock. Any future determination
as to the declaration and payment of dividends, if any, will be at the discretion of our board of directors, subject to applicable laws and will depend on then existing conditions, including our financial condition, operating results, contractual
restrictions, capital requirements, business prospects, and other factors our board of directors may deem relevant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="supptoc446052_10"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following discussion is a summary of the material U.S. federal income tax consequences of the purchase, ownership and disposition of the shares of common stock and
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants, which we refer to collectively as the &#147;Securities,&#148; issued pursuant to this offering, but does not purport to be a complete analysis of all potential tax effects. The effects of
other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local or foreign tax laws are not discussed. This discussion is based on the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;), Treasury
Regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements of the U.S. Internal Revenue Service (the &#147;IRS&#148;) in effect as of the date of this offering. These authorities may change or be
subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely affect a holder of the Securities. We have not sought and will not seek any rulings from the IRS
regarding the matters discussed below. There can be no assurance the IRS or a court will not take a contrary position regarding the tax consequences of the purchase, ownership and disposition of the Securities. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This discussion is limited to holders that hold the Securities as a &#147;capital asset&#148; within the meaning of Section&nbsp;1221 of the Code (generally, property
held for investment). This discussion does not address all U.S. federal income tax consequences relevant to a holder&#146;s particular circumstances, including the impact of the alternative minimum tax provisions of the Code or the unearned income
Medicare contribution tax. In addition, it does not address consequences relevant to holders subject to particular rules, including, without limitation: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">U.S. expatriates and certain former citizens or long-term residents of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons holding the Securities as part of a hedge, straddle or other risk reduction strategy or as part of a conversion
transaction or other integrated investment; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">banks, insurance companies and other financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">brokers, dealers or traders in securities; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&#147;controlled foreign corporations,&#148; &#147;passive foreign investment companies&#148; and corporations that
accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax purposes (and investors
therein); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations or governmental organizations; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons deemed to sell the Securities under the constructive sale provisions of the Code; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons holding the Securities as &#147;qualified small business stock&#148; within the meaning of Section&nbsp;1202 of
the Code; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons who hold or receive the Securities pursuant to the exercise of any employee stock option or otherwise as
compensation; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">persons subject to special tax accounting rules as a result of any item of gross income with respect to the Securities
being taken into account in an &#147;applicable financial statement&#148; (as defined in the Code); and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&#147;qualified foreign pension funds&#148; as defined in Section&nbsp;897(l)(2) of the Code and entities all of the
interests of which are held by qualified foreign pension funds; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plans. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If a partnership (or other entity treated as a partnership for U.S. federal income tax purposes) holds the Securities, the tax treatment of a partner in the partnership
will depend on the status of the partner, the activities of the partnership and certain determinations made at the partner level. Accordingly, partnerships holding the Securities and the partners in such partnerships should consult their tax
advisors regarding the U.S. federal income tax consequences to them. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>THIS DISCUSSION IS FOR INFORMATION PURPOSES ONLY AND IS NOT INTENDED AS LEGAL OR TAX ADVICE. INVESTORS SHOULD
CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF THE SECURITIES ARISING UNDER THE U.S. FEDERAL
ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL OR <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> TAXING JURISDICTION OR UNDER ANY APPLICABLE INCOME TAX TREATY. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Treatment of <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Although not free from doubt, a <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant should be treated as a share of our common stock for U.S. federal income tax
purposes, and a holder of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants should generally be taxed in the same manner as a holder of common stock, as described below. Except where specifically noted below, the following discussion
assumes the characterization described above is respected for U.S. federal income tax purposes. However, this characterization is not binding on the IRS, and the IRS may treat the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants as
warrants to acquire shares of our common stock. If so, the tax consequences with respect to an investment in our <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants could differ. Holders should consult their tax advisors regarding the risks
associated with the acquisition of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants pursuant to this offering (including alternative characterizations). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Tax Considerations Applicable to U.S. Holders </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Definition of a U.S.
Holder </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For purposes of this discussion, a &#147;U.S. holder&#148; is any beneficial owner of the Securities that, for U.S. federal income tax purposes, is
or is treated as any of the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a corporation created or organized under the laws of the United States, any state thereof or the District of Columbia;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a trust that (1)&nbsp;is subject to the primary supervision of a U.S. court and the control of one or more
United&nbsp;States persons (within the meaning of Section&nbsp;7701(a)(30) of the Code), or (2)&nbsp;has made a valid election under applicable Treasury Regulations to be treated as a United States person. </P></TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Distributions </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not anticipate declaring or paying in the
foreseeable future any cash dividends on our common stock. However, if we do make distributions on the Securities, such distributions of cash or property on the Securities will constitute dividends to the extent paid out of our current or
accumulated earnings and profits, as determined for U.S. federal income tax purposes. Dividends received by a corporate U.S. holder may be eligible for a dividends received deduction, subject to applicable limitations. Dividends received by certain <FONT
STYLE="white-space:nowrap">non-corporate</FONT> U.S. holders, including individuals, are generally taxed at the lower applicable capital gains rate provided certain holding period and other requirements are satisfied. Distributions in excess of our
current and accumulated earnings and profits will constitute a return of capital and first be applied against and reduce a U.S. holder&#146;s adjusted tax basis in its Securities, but not below zero. Any excess will be treated as capital gain and
will be treated as described below in the section relating to the sale or disposition of the Securities. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Sale or Other Taxable Disposition of the Securities
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon the sale, exchange or other taxable disposition of the Securities, a U.S. holder generally will recognize capital gain or loss equal to the difference
between (i)&nbsp;the amount of cash and the fair market value of any property received upon the sale, exchange or other taxable disposition and (ii) such U.S. holder&#146;s adjusted tax basis in the Securities. Such capital gain or loss will be
long-term capital gain or loss if the U.S. holder&#146;s holding period in such Securities is more than one year at the time of the sale, exchange or other taxable disposition. Long-term capital gains recognized by certain <FONT
STYLE="white-space:nowrap">non-corporate</FONT> U.S. holders, including individuals, generally will be subject to reduced rates of U.S. federal income tax. The deductibility of capital losses is subject to certain limitations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Exercise of <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A U.S. holder generally will not recognize gain or loss (other than with respect to cash paid in lieu of a fractional share) upon the exercise of a <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrant. Upon exercise, the holding period of a <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant should carry over to the share of common stock received. Similarly, the tax basis of the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrant should carry over to the share of common stock received upon exercise, increased by the exercise price. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In
certain circumstances, the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants may be exercised on a cashless basis. The U.S. federal income tax treatment of an exercise of a warrant on a cashless basis is not clear, and could differ from
the consequences described above. It is possible that a cashless exercise could be a taxable event. U.S. holders are urged to consult their tax advisors as to the consequences of an exercise of a <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrant on a cashless basis, including with respect to their holding period and tax basis in the shares of common stock received upon exercise. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Constructive
Dividends on <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A holder of a <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant may, in
some circumstances, be deemed to have received a distribution subject to U.S. federal income tax as a result of an adjustment or the <FONT STYLE="white-space:nowrap">non-occurrence</FONT> of an adjustment to the exercise price or to the number of
shares of common stock issuable upon exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant. U.S. holders should consult their tax advisors regarding the proper treatment of any adjustments (or the
<FONT STYLE="white-space:nowrap">non-occurrence</FONT> of any adjustments) to the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Information
Reporting and Backup Withholding </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A U.S. holder may be subject to information reporting and backup withholding when such holder receives payments on the
Securities (including constructive dividends) or receives proceeds from the sale or other taxable disposition of the Securities. Certain U.S. holders are exempt from backup withholding, including corporations and certain <FONT
STYLE="white-space:nowrap">tax-exempt</FONT> organizations. A U.S. holder will be subject to backup withholding if such holder is not otherwise exempt and such holder: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">fails to furnish the holder&#146;s taxpayer identification number, which for an individual is ordinarily his or her
social security number; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">furnishes an incorrect taxpayer identification number; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">is notified by the IRS that the holder previously failed to properly report payments of interest or dividends; or fails
to certify under penalties of perjury that the holder has furnished a correct taxpayer identification number and that the IRS has not notified the holder that the holder is subject to backup withholding. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or a credit against a U.S. holder&#146;s
U.S. federal income tax liability, provided the required information is timely furnished to the IRS. U.S. holders should consult their tax advisors regarding their qualification for an exemption from backup withholding and the procedures for
obtaining such an exemption. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Tax Considerations Applicable to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For purposes of this discussion, a <FONT STYLE="white-space:nowrap">&#147;non-U.S.</FONT> holder&#148; is a beneficial owner of the Securities that is neither a U.S.
holder nor an entity treated as a partnership for U.S. federal income tax purposes. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Distributions </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not anticipate declaring or paying in the foreseeable future any cash dividends on our common stock. However, if we do make distributions on the Securities, such
distributions of cash or property on the Securities will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles.
Distributions in excess of our current and accumulated earnings and profits will first constitute a return of capital and be applied against and reduce a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s adjusted tax basis in its
Securities, but not below zero. Any excess will be treated as capital gain and will be treated as described below in the section relating to the sale or disposition of the Securities. Because we may not know the extent to which a distribution is a
dividend for U.S. federal income tax purposes at the time it is made, for purposes of the withholding rules discussed below we or the applicable withholding agent may treat the entire distribution as a dividend. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Dividends paid to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder of the Securities that are not
effectively connected with the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s conduct of a trade or business within the United States will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the
dividends (or such lower rate specified by an applicable income tax treaty). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders will be entitled to a
reduction in or an exemption from withholding on dividends as a result of either (a)&nbsp;an applicable income tax treaty or (b)&nbsp;the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder holding the Securities in connection with the conduct
of a trade or business within the United States and dividends being effectively connected with that trade or business. To claim such a reduction in or exemption from withholding, the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder must
provide the applicable withholding agent with a properly executed (a)&nbsp;IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or other applicable
documentation) claiming an exemption from or reduction of the withholding tax under the benefit of an income tax treaty between the United States and the country in which the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder resides or is
established, or (b)&nbsp;IRS Form <FONT STYLE="white-space:nowrap">W-8ECI</FONT> stating that the dividends are not subject to withholding tax because they are effectively connected with the conduct by the
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder of a trade or business within the United States, as may be applicable. These certifications must be provided to the applicable withholding agent prior to the payment of dividends and may need
to be updated periodically. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders that do not timely provide the applicable withholding agent with the required certification, but that qualify for a reduced rate under an applicable income tax
treaty, may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If dividends paid to a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder are effectively connected with the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s conduct of a trade or business within the United States (and, if required by an applicable income tax
treaty, the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder maintains a permanent establishment in the United States to which such dividends are attributable), then, although exempt from U.S. federal withholding tax (provided the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder provides appropriate certification, as described above), the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be subject to U.S. federal income tax on such dividends on a net income basis
at the regular rates applicable to U.S. persons. In addition, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is a corporation may be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable
income tax treaty) on its effectively connected earnings and profits for the taxable year that are attributable to such dividends, as adjusted for certain items. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax
advisors regarding their entitlement to benefits under any applicable income tax treaty. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Exercise of <FONT STYLE="white-space:nowrap">Pre-funded</FONT>
Warrants </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will not be subject to U.S. federal income tax on the exercise of <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants into shares of common stock (except to the extent cash is received in lieu of fractional common shares and certain other conditions are present, as described below under &#147;&#151;<I>Sale or
Other Taxable Disposition of the Securities</I>&#148;). However, if a cashless exercise of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants results in a taxable exchange, as described in &#147;<I>&#151;Tax Considerations Applicable to
U.S. Holders&#151;Exercise of <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants</I>,&#148; the rules described below under &#147;&#151;<I>Sale or Other Taxable Disposition of the Securities</I>&#148; would apply. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Sale or Other Taxable Disposition of the Securities </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to the
discussions below on backup withholding and foreign accounts, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will not be subject to U.S. federal income tax on any gain realized upon the sale or other disposition of the Securities unless:
</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s conduct of a
trade or business within the United States (and, if required by an applicable income tax treaty, the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder maintains a permanent establishment in the United States to which such gain is
attributable); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a nonresident alien individual present in the United States
for 183 days or more during the taxable year of the disposition and certain other requirements are met; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the Securities constitute U.S. real property interests (&#147;USRPIs&#148;) by reason of our status as a U.S. real
property holding corporation (&#147;USRPHC&#148;) for U.S. federal income tax purposes. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Gain described in the first bullet point above will
generally be subject to U.S. federal income tax on a net income basis at the regular rates applicable to U.S. persons. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is a foreign corporation also may be subject to a branch profits
tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on such effectively connected gain, as adjusted for certain items. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder described in the second bullet point above will be subject
to U.S. federal income tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on any gain realized upon the sale or other taxable disposition of the Securities, which may be offset by certain U.S. source capital
losses of the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder (even though the individual is not considered a resident of the United States) provided the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder has timely filed U.S. federal
income tax returns with respect to such losses. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">With respect to the third bullet point above, we believe we are not currently and do not anticipate becoming a
USRPHC. Because the determination of whether we are a USRPHC depends on the fair market value of our USRPIs relative to the fair market value of our other business assets and our <FONT STYLE="white-space:nowrap">non-U.S.</FONT> real property
interests, however, there can be no assurance we are not a USRPHC or will not become one in the future. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders
should consult their tax advisors regarding potentially applicable income tax treaties that may provide for different rules. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Constructive Dividends on <FONT
STYLE="white-space:nowrap">Pre-funded</FONT> Warrants </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A non-U.S. holder of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants can be treated as
receiving deemed payment of a taxable dividend under certain circumstances as a result of an adjustment or the <FONT STYLE="white-space:nowrap">non-occurrence</FONT> of an adjustment to the exercise price or number of shares of common stock issuable
upon exercise of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant. Any resulting withholding tax attributable to deemed dividends may be collected from other amounts payable or distributable to the
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding the proper treatment of any adjustments to the
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Information Reporting and Backup Withholding </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will not be subject to backup withholding with respect to distributions on the Securities we make to the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder (including constructive dividends), provided the applicable withholding agent does not have actual knowledge or reason to know such holder is a United States person and the holder certifies its <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> status, such as by providing a valid IRS Form <FONT STYLE="white-space:nowrap">W-8BEN,</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or <FONT
STYLE="white-space:nowrap">W-8ECI,</FONT> or other applicable certification. However, information returns generally will be filed with the IRS in connection with any distributions (including deemed distributions) made on the Securities to the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder, regardless of whether any tax was actually withheld. Copies of these information returns may also be made available under the provisions of a specific treaty or agreement to the tax authorities of
the country in which the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder resides or is established. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Information reporting and backup withholding may apply
to the proceeds of a sale or other taxable disposition of the Securities within the United States, and information reporting may (although backup withholding generally will not) apply to the proceeds of a sale or other taxable disposition of the
Securities outside the United States conducted through certain U.S.-related financial intermediaries, in each case, unless the beneficial owner certifies under penalty of perjury that it is a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder
on IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E,</FONT></FONT> or other applicable form (and the payor does not have actual knowledge or reason to know that the
beneficial owner is a U.S. person) or such owner otherwise establishes an exemption. Proceeds of a disposition of the Securities conducted through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> broker generally will not be subject to backup withholding or information reporting. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Backup withholding is not an
additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or a credit against a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s U.S. federal income tax liability, provided the required
information is timely furnished to the IRS. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Additional Withholding Tax on Payments Made to Foreign Accounts </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Withholding taxes may be imposed under the Foreign Account Tax Compliance Act (&#147;FATCA&#148;) on certain types of payments made to
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> financial institutions and certain other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entities. Specifically, a 30% withholding tax may be imposed on dividends (including deemed dividends) paid on
the Securities, or (subject to the proposed Treasury Regulations discussed below) gross proceeds from the sale or other disposition of the Securities paid to a &#147;foreign financial institution&#148; or a
<FONT STYLE="white-space:nowrap">&#147;non-financial</FONT> foreign entity&#148; (each as defined in the Code), unless (1)&nbsp;the foreign financial institution undertakes certain diligence and reporting obligations, (2)&nbsp;the <FONT
STYLE="white-space:nowrap">non-financial</FONT> foreign entity either certifies it does not have any &#147;substantial United States owners&#148; (as defined in the Code) or furnishes identifying information regarding each substantial United States
owner, or (3)&nbsp;the foreign financial institution or <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity otherwise qualifies for an exemption from these rules. If the payee is a foreign financial institution and is subject to the
diligence and reporting requirements in (1)&nbsp;above, it must enter </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
into an agreement with the U.S. Department of the Treasury requiring, among other things, that it undertake to identify accounts held by certain &#147;specified United&nbsp;States persons&#148;
or &#147;United States-owned foreign entities&#148; (each as defined in the Code), annually report certain information about such accounts, and withhold 30% on certain payments to <FONT STYLE="white-space:nowrap">non-compliant</FONT> foreign
financial institutions and certain other account holders. Foreign financial institutions located in jurisdictions that have an intergovernmental agreement with the United States governing FATCA may be subject to different rules. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the applicable Treasury Regulations and administrative guidance, withholding under FATCA generally applies to payments of dividends (including deemed dividends).
Because we may not know the extent to which a distribution (including a deemed distribution) is a dividend for U.S. federal income tax purposes at the time it is made, for purposes of these withholding rules we or the applicable withholding agent
may treat the entire distribution as a dividend. While withholding under FATCA would have applied also to payments of gross proceeds from the sale or other disposition of the Securities on or after January&nbsp;1, 2019, proposed Treasury Regulations
eliminate FATCA withholding on payments of gross proceeds entirely. Taxpayers generally may rely on these proposed Treasury Regulations until final Treasury Regulations are issued. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prospective investors should consult their tax advisors regarding the potential application of these withholding provisions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="supptoc446052_11"></A>DESCRIPTION OF SECURITIES WE ARE OFFERING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Common Stock </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are offering shares of our common stock in this offering.
See &#147;Description of Capital Stock&#148; in the accompanying prospectus for more information regarding our shares of common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT
STYLE="white-space:nowrap">Pre-funded</FONT> Warrants </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following is a summary of the material attributes and characteristics of the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants. The form of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants will be provided to the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant purchasers in this offering and will be
filed as an exhibit to a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> in connection with this offering and incorporated by reference into the registration statement of which this prospectus supplement forms a part. The
following summary is subject in all respects to the provisions contained in the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. <FONT STYLE="white-space:nowrap">Pre-funded</FONT> warrants will be issued in certificated form only. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Duration and Exercise Price </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant entitles the holder thereof to purchase shares of our common stock at an exercise price equal to $0.001 per share. Each <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant will be
exercisable at any time beginning on the date of issuance. The number of shares of our common stock issuable upon exercise of each <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant is subject to appropriate adjustment in the event of
certain stock dividends, stock splits, reorganizations or similar events affecting our common stock and the exercise price. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Exercisability </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The holder of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant may exercise the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant by delivering
an exercise notice, completed and duly signed, and payment in cash of the exercise price for the number of shares of our common stock for which the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant is being exercised. The holder of the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrant may also satisfy its obligation to pay the exercise price through a &#147;cashless exercise,&#148; in which the holder receives the net value of the
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant in shares of common stock determined according to the formula set forth in the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant. Upon a holder&#146;s exercise of the <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrant, we will issue the shares of common stock to which the holder is entitled pursuant to such exercise within two trading days after the exercise date. A holder of the
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant will not be entitled to exercise any portion of such <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant that, upon giving effect to such exercise, would cause the aggregate number of
shares of our common stock beneficially owned by such holder (together with its affiliates and any other persons whose beneficial ownership of common stock would be aggregated with the holder for purposes of Section&nbsp;13(d) of the Exchange Act)
to exceed 9.99% of the total number of then issued and outstanding shares of common stock, as such percentage ownership is determined in accordance with the terms of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant and subject to such
holder&#146;s rights under the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant to increase or decrease such percentage to any other percentage not in excess of 19.99% upon at least 61 days&#146; prior notice from such holder to us. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Fundamental Transaction </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event of any fundamental transaction,
as described in the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants and generally including any merger with or into another entity, sale of all or substantially all of our assets, tender offer or exchange offer, or reclassification of
our shares of common stock, then upon any subsequent exercise of a <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant, the holder will have the right to receive as alternative consideration, for each share of common stock that would have
been issuable upon such exercise immediately prior to the occurrence of such fundamental transaction, the number of shares of common stock of the successor or acquiring corporation of our company, if it is the surviving corporation, and any
additional consideration receivable upon or as a result of such transaction by a holder of the number of shares of common stock for which the warrant is exercisable immediately prior to such event. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Transferability </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to applicable laws, a <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrant may be transferred at the option of the holder upon surrender of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant to us together with the appropriate instruments of transfer and
payment of funds sufficient to pay any transfer taxes (if applicable). </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Exchange Listing </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There is no trading market available for the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants on any securities exchange or nationally recognized trading
system. We do not intend to list the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants on The Nasdaq Global Select Market or any securities exchange or nationally recognized trading system. We will initially serve as the warrant agent
under the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Right as a Stockholder </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Except as otherwise provided in the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants or by virtue of such holder&#146;s ownership of shares of our common
stock, the holders of the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants do not have the rights or privileges of holders of our common stock, including any voting rights, until they exercise their
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="supptoc446052_12"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to the terms and conditions set forth in the underwriting agreement, dated December&nbsp;20, 2023, between us, Jefferies LLC and Cowen and Company, LLC, as the
representatives of the underwriters (the &#147;Representatives&#148;) named below and the joint book-running managers of this offering, we have agreed to sell to the underwriters, and each of the underwriters has agreed, severally and not jointly,
to purchase from us the respective number of shares of common stock and the number of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants shown opposite its name below:<SUP STYLE="font-size:75%; vertical-align:top"> </SUP> </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>UNDERWRITER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF</B><br><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF</B><br><B><FONT STYLE="white-space:nowrap">PRE-FUNDED</FONT></B><br><B>WARRANTS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,456,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,879,175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cowen and Company, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,578,687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,500,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,035,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,379,861</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriting agreement provides that the obligations of the several underwriters are subject to certain conditions precedent such as the receipt by the underwriters
of officers&#146; certificates and legal opinions and approval of certain legal matters by their counsel. The underwriting agreement provides that the underwriters will purchase all of the shares of common stock and
<FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants if any of them are purchased. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the nondefaulting underwriters may be increased or the
underwriting agreement may be terminated. We have agreed to indemnify the underwriters and certain of their controlling persons against certain liabilities, including liabilities under the Securities Act, and to contribute to payments that the
underwriters may be required to make in respect of those liabilities. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters have advised us that, following the completion of this offering, they
currently intend to make a market in the common stock as permitted by applicable laws and regulations. However, the underwriters are not obligated to do so, and the underwriters may discontinue any market-making activities at any time without notice
in their sole discretion. Accordingly, no assurance can be given as to the liquidity of the trading market for the common stock, that you will be able to sell any of the common stock held by you at a particular time or that the prices that you
receive when you sell will be favorable. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters are offering the shares of common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants
subject to their acceptance of the shares of common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants from us and subject to prior sale. The underwriters reserve the right to withdraw, cancel or modify offers to the public and to
reject orders in whole or in part.&nbsp;&nbsp;&nbsp;&nbsp; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Commission and Expenses </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters may allow, and certain dealers may reallow, a discount from the concession not in excess of $0.10368 per share of common stock and $0.10368 per <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrant to certain brokers and dealers. After the offering, the public offering price, concession and reallowance to dealers may be reduced by the Representatives. No such reduction will change the amount
of proceeds to be received by us as set forth on the cover page of this prospectus. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table shows the public offering price, the underwriting discounts
and commissions that we are to pay the underwriters and the proceeds, before expenses, to us in connection with this offering. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PER&nbsp;SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">PER&nbsp;PRE-FUNDED</FONT></B><br><B>WARRANT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.880</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.879</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">125,016,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Underwriting discounts and commissions paid by us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,500,985</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds to us, before expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.7072</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.7063</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">117,515,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We estimate expenses payable by us in connection with this offering, other than the underwriting discounts and commissions referred to above, will be approximately
$400,000. We have agreed to reimburse the underwriters for certain of their expenses in an amount up to $35,000. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Listing </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our common stock
is listed on the Nasdaq Global Select Market under the trading symbol &#147;ANNX&#148;. We do not plan to list the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants on the Nasdaq Global Select Market or any other securities exchange or
trading market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Stamp Taxes </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If you purchase shares of common stock or <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants offered in this prospectus, you may be required to pay stamp taxes and other charges under the laws and practices of the country of purchase, in addition to the offering price listed on the cover
page of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>No Sales of Similar Securities</B> </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We, our
officers, directors and certain securityholders have agreed, subject to specified exceptions, not to directly or indirectly: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell,
grant any option, right or warrant to purchase, or otherwise transfer or dispose of, directly or indirectly, or file with, or submit to, the SEC a registration statement under the Securities Act relating to, any shares of common stock or any
securities convertible into or exercisable or exchangeable for our common stock, or publicly disclose the intention to make any offer, sale, pledge, disposition, submission or filing; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">enter into any swap, hedging, or other agreement that transfers, in whole or in part, any of the economic consequences of
ownership of our common stock or any such other securities; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">publicly announce an intention to do any of the foregoing for a period of 60 days after the date of this prospectus
without the prior written consent of the Representatives. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Notwithstanding the foregoing, the securityholder may transfer shares of common stock:
(i)&nbsp;that are to be sold hereunder, (ii)&nbsp;through the grant or issuance of any shares of common stock or any securities or other awards (including without limitation options, restricted stock or restricted stock units) convertible into,
exercisable for, or that represent the right to receive, shares of common stock pursuant to any Company stock plan or otherwise in equity compensation arrangements described in the registration statement and the prospectus supplement and the
issuance of shares of common stock underlying or pursuant to such securities or awards, (iii)&nbsp;that are issued upon the conversion, exercise (whether such exercise is for cash or &#147;cashless&#148;), vesting or exchange of convertible,
exercisable, exchangeable or other securities outstanding on the date of the underwriting agreement and described in the registration statement and the prospectus supplement granted pursuant to any plan in effect on the date of the underwriting
agreement and described in the registration statement and the prospectus supplement, (iv)&nbsp;that are filed by the Company under any registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> or a successor form thereto relating to
any Company stock plan described in the registration statement and the prospectus supplement, and (v)&nbsp;or any securities convertible into or exchangeable for, or that represent the right to receive, shares of common stock issued in connection
with any bona fide licensing, commercialization, joint venture, technology transfer, acquisition, development collaboration or partnership or other strategic transaction, provided that the aggregate number of shares of common stock or securities
convertible into or exercisable for common stock (on an <FONT STYLE="white-space:nowrap">as-converted</FONT> or <FONT STYLE="white-space:nowrap">as-exercised</FONT> basis, as the case may be) that the Company may sell or issue or agree to sell or
issue as described in this clause (v)&nbsp;shall not exceed 5% of the total number of shares of common stock issued and outstanding immediately following the completion of the transactions contemplated by the underwriting agreement; provided that
the recipient of any such shares of common stock or securities issued pursuant to clauses (ii), (iii), and (v)&nbsp;during the restricted period shall enter into a <FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreement, substantially
in the form of the agreed <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, the foregoing restrictions shall not apply to (i)&nbsp;the
exercise on a cash basis of any option to purchase shares of common stock granted under any stock incentive plan or stock purchase plan of the Company disclosed in the prospectus supplement, provided that the underlying shares of common stock shall
continue to be subject to the restrictions on transfer set forth in the agreed <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, and provided, further, that any required filing under Section&nbsp;16 of the Exchange Act shall clearly
indicate in the footnotes thereto that the filing relates to the circumstances described in this clause (i)&nbsp;above and no other public announcement shall be required or shall be made voluntarily in connection with such transfer or surrender,
(ii)&nbsp;a trading plan pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Exchange Act (each such plan, a &#147;Trading Plan&#148;) for the transfer of common stock, provided that such Trading Plan does not provide for any transfers of common stock during the <FONT
STYLE="white-space:nowrap">lock-up</FONT> period, and provided, further, that no filing under Section&nbsp;16 of the Exchange Act or other public announcement shall be required or shall be made voluntarily in connection therewith during the <FONT
STYLE="white-space:nowrap">lock-up</FONT> period, (iii)&nbsp;the transfers or dispositions of shares of common stock under a Trading Plan that is existing as of the date hereof, provided that no filing under the Exchange Act or other public filing,
report or announcement shall be voluntarily made during the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, and to the extent a public announcement or filing under the Exchange Act, if any, is required to be made by or on behalf of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> party, such announcement or filing shall include a statement to the effect that such dispositions were made pursuant to such Trading Plan, (iv)&nbsp;the transfer or disposal of shares of common stock
acquired in the public offering or on the open market following the public offering, provided that no filing under Section&nbsp;16 of the Exchange Act or other public announcement shall be required or shall be made voluntarily in connection with
such transfer or disposition during the <FONT STYLE="white-space:nowrap">lock-up</FONT> period (other than a required filing on a Schedule 13F or 13G), (v) the transfer or surrender to the Company shares of common stock (or any security convertible
into common stock)&nbsp;(a) pursuant to a right of first refusal described in the prospectus supplement with respect to transfers of such shares of common stock or other securities, provided that no filing under Section&nbsp;16 of the Exchange Act
or other public announcement shall be required or shall be made voluntarily in connection with such transfer or disposition during the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, or (b)&nbsp;to the Company for purposes of exercising or
settling (including for the payment of tax withholdings due as a result of such exercise or settlement) on a &#147;net exercise,&#148; &#147;net settlement&#148; or &#147;cashless&#148; basis any equity award, provided such equity award was granted
under a stock incentive plan or stock purchase plan of the Company described in the prospectus supplement, and provided, further, that no filing under Section&nbsp;16 of the Exchange Act or other public filing, report or announcement shall be
voluntarily made during the <FONT STYLE="white-space:nowrap">lock-up</FONT> period (other than a filing on a Form 5 made after the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period referred to above), and if the <FONT
STYLE="white-space:nowrap">lock-up</FONT> party is required to file a report under Section&nbsp;16 of the Exchange Act during the <FONT STYLE="white-space:nowrap">lock-up</FONT> period, the <FONT STYLE="white-space:nowrap">lock-up</FONT> party shall
clearly indicate in the footnotes thereto the nature and conditions of such transfer, and (vi)&nbsp;the transfer or disposal of lockup securities by operation of law pursuant to a qualified domestic order or in connection with a divorce settlement
or other court order, provided that the recipient of such shares of common stock shall execute and deliver to the Representatives a <FONT STYLE="white-space:nowrap">lock-up</FONT> letter in the form of the agreed
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, provided, further, that any required filing under Section&nbsp;16 of the Exchange Act shall clearly indicate in the footnotes thereto that the filing relates to the circumstances described
in this clause (vi)&nbsp;above. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Jefferies LLC and Cowen and Company, LLC, may, in their sole discretion and at any time or from time to time before the termination
of the <FONT STYLE="white-space:nowrap">60-day</FONT> period release all or any portion of the securities subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. There are no existing agreements between the underwriters and any of our
shareholders who will execute a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, providing consent to the sale of shares prior to the expiration of the <FONT STYLE="white-space:nowrap">lock-up</FONT> period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Stabilization </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters have advised us that they, pursuant to
Regulation M under the Securities Exchange Act of 1934, as amended, certain persons participating in the offering may engage in short sale transactions, stabilizing transactions, syndicate covering transactions or the imposition of penalty bids in
connection with this offering. These activities may have the effect of stabilizing or maintaining the market price of the common stock at a level above that which might otherwise prevail in the open market. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A stabilizing bid is a bid for the purchase of shares of common stock on behalf of the underwriters for the purpose of fixing or maintaining the price of the common
stock. A syndicate covering transaction is the bid for or the purchase of shares of common stock on behalf of the underwriters to reduce a short position incurred by the underwriters in connection with the offering. Similar to other purchase
transactions, the underwriter&#146;s purchases to cover the syndicate short sales may have the effect of raising or maintaining the market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a
result, the price of our common stock may be higher than the price that might otherwise exist in the open market. A penalty bid is an arrangement permitting the underwriters to reclaim the selling concession otherwise accruing to a syndicate member
in connection with the offering if the common stock originally sold by such syndicate member are purchased in a syndicate covering transaction and therefore have not been effectively placed by such syndicate member. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Neither we nor any of the underwriters make any representation or prediction as to the direction or magnitude of any
effect that the transactions described above may have on the price of our common stock. The underwriters are not obligated to engage in these activities and, if commenced, any of the activities may be discontinued at any time. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters may also engage in passive market making transactions in our common stock on the Nasdaq Global Select Market in accordance with Rule&nbsp;103 of
Regulation&nbsp;M during a period before the commencement of offers or sales of shares of our common stock in this offering and extending through the completion of distribution. A passive market maker must display its bid at a price not in excess of
the highest independent bid of that security. However, if all independent bids are lowered below the passive market maker&#146;s bid, that bid must then be lowered when specified purchase limits are exceeded. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Electronic Distribution </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A prospectus in electronic format may be made
available by <FONT STYLE="white-space:nowrap">e-mail</FONT> or on the web sites or through online services maintained by one or more of the underwriters or their affiliates. In those cases, prospective investors may view offering terms online and
may be allowed to place orders online. The underwriters may agree with us to allocate a specific number of shares of common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants for sale to online brokerage account holders. Any such
allocation for online distributions will be made by the underwriters on the same basis as other allocations. Other than the prospectus in electronic format, the information on the underwriters&#146; web sites and any information contained in any
other web site maintained by any of the underwriters is not part of this prospectus, has not been approved and/or endorsed by us or the underwriters and should not be relied upon by investors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Other Activities and Relationships </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriter and certain of its
affiliates are full service financial institutions engaged in various activities, which may include securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging,
financing and brokerage activities. The underwriter and certain of its affiliates have, from time to time, performed, and may in the future perform, various commercial and investment banking and financial advisory services for us and our affiliates,
for which they received or will receive customary fees and expenses. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the ordinary course of their various business activities, the underwriter and certain of
its affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their
customers, and such investment and securities activities may involve securities and/or instruments issued by us and our affiliates.&nbsp;&nbsp;&nbsp;&nbsp;If the underwriters or their respective affiliates have a lending relationship with us, they
routinely hedge their credit exposure to us consistent with their customary risk management policies. The underwriters and their respective affiliates may hedge such exposure by entering into transactions which consist of either the purchase of
credit default swaps or the creation of short positions in our securities or the securities of our affiliates, including potentially the common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants offered hereby. Any such short
positions could adversely affect future trading prices of the common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants offered hereby. The underwriters and certain of their respective affiliates may also communicate independent
investment recommendations, market color or trading ideas and/or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long and/or short
positions in such securities and instruments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Disclaimers About <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Jurisdictions </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Notice to Prospective Investors in Canada </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>(A) Resale Restrictions
</I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The distribution of common stock and <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants (collectively, the <I>Securities</I>) in Canada is being made
only in the provinces of Ontario, Quebec, Alberta, British Columbia, Manitoba, New Brunswick and Nova Scotia on a private placement basis exempt from the requirement that we prepare and file a prospectus with the Securities regulatory authorities in
each province where trades of these securities are made. Any resale of the securities in Canada must be made under applicable securities laws which may vary depending on the relevant jurisdiction, and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
which may require resales to be made under available statutory exemptions or under a discretionary exemption granted by the applicable Canadian securities regulatory authority. Purchasers are
advised to seek legal advice prior to any resale of the securities.</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>(B) Representations of Canadian Purchasers</I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">By purchasing the Securities in Canada and accepting delivery of a purchase confirmation, a purchaser is representing to us and the dealer from whom the purchase
confirmation is received that: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the purchaser is entitled under applicable provincial securities laws to purchase the Securities without the benefit of a
prospectus qualified under those securities laws as it is an &#147;accredited investor&#148; as defined under National Instrument <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">45-106-Prospectus</FONT></FONT> Exemptions,
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the purchaser is a &#147;permitted client&#148; as defined in National Instrument <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">31-103-Registration</FONT></FONT> Requirements, Exemptions and Ongoing Registrant Obligations, </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">where required by law, the purchaser is purchasing as principal and not as agent, and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the purchaser has reviewed the text above under Resale Restrictions. </P></TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>(C) Conflicts of Interest</I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Canadian purchasers are hereby notified that the
underwriter is relying on the exemption set out in section 3A.3 or 3A.4, if applicable, of National Instrument <FONT STYLE="white-space:nowrap">33-105&#151;Underwriting</FONT> Conflicts from having to provide certain conflict of interest disclosure
in this document. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>(D) Statutory Rights of Action</I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Securities legislation
in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if the offering memorandum (including any amendment thereto) such as this document contains a misrepresentation, provided that the remedies
for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser of these Securities in Canada should refer to any applicable
provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with a legal advisor. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>(E)
Enforcement of Legal Rights</I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All of our directors and officers as well as the experts named herein may be located outside of Canada and, as a result, it may not
be possible for Canadian purchasers to effect service of process within Canada upon us or those persons. All or a substantial portion of our assets and the assets of those persons may be located outside of Canada and, as a result, it may not be
possible to satisfy a judgment against us or those persons in Canada or to enforce a judgment obtained in Canadian courts against us or those persons outside of Canada.</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>(F) Taxation and Eligibility for Investment</I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Canadian purchasers of the
Securities should consult their own legal and tax advisors with respect to the tax consequences of an investment in the Securities in their particular circumstances and about the eligibility of the Securities for investment by the purchaser under
relevant Canadian legislation. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Notice to Prospective Investors in the European Economic Area</I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In relation to each Member State of the European Economic Area (each, a <I>Relevant State</I>), no Securities have been offered or will be offered pursuant to the
offering to the public in that Relevant State prior to the publication of a prospectus in relation to the Securities which has been approved by the competent authority in that Relevant State or, where appropriate, approved in another Relevant State
and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation, except that Securities may be offered to the public in that Relevant State at any time:</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">to any legal entity which is a &#147;qualified investor&#148; as defined under Article 2 of the Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the Prospectus
Regulation), subject to obtaining the prior consent of the Representatives for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">provided that no such offer of Securities to publish a prospectus pursuant to Article 3 of the Prospectus Regulation, or supplement a prospectus pursuant to Article 23
of the Prospectus Regulation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to any Securities
in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any Securities to be offered so as to enable an investor to decide to purchase or subscribe for any Securities, and
the expression &#147;Prospectus Regulation&#148; means Regulation (EU) 2017/1129, as amended. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Notice to Prospective Investors in Hong Kong</I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No Securities have been offered or sold, and no Securities may be offered or sold, in Hong Kong, by means of any document, other than to persons whose ordinary business
is to buy or sell shares or debentures, whether as principal or agent; or to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong (<I>SFO</I>) and any rules made under that Ordinance; or in
other circumstances which do not result in the document being a &#147;prospectus&#148; as defined in the Companies Ordinance (Cap. 32) of Hong Kong (<I>CO</I>) or which do not constitute an offer or invitation to the public for the purpose of the CO
or the SFO. No document, invitation or advertisement relating to the Securities has been issued or may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed
at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted under the securities laws of Hong Kong) other than with respect to securities which are or are intended to be disposed of only to persons
outside Hong Kong or only to &#147;professional investors&#148; as defined in the SFO and any rules made under that Ordinance.</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus supplement has not
been registered with the Registrar of Companies in Hong Kong. Accordingly, this prospectus supplement may not be issued, circulated or distributed in Hong Kong, and the Securities may not be offered for subscription to members of the public in Hong
Kong. Each person acquiring the Securities will be required, and is deemed by the acquisition of the Securities, to confirm that he is aware of the restriction on offers of the Securities described in this prospectus supplement and the relevant
offering documents and that he is not acquiring, and has not been offered any Securities in circumstances that contravene any such restrictions. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Notice to
Prospective Investors in Israel</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This document does not constitute a prospectus under the Israeli Securities Law, 5728-1968, or the Securities Law, and has
not been filed with or approved by the Israel Securities Authority. In Israel, this prospectus supplement is being distributed only to, and is directed only at, and any offer of the Securities is directed only at, (i)&nbsp;a limited number of
persons in accordance with the Israeli Securities Law and (ii)&nbsp;investors listed in the first addendum, or the Addendum, to the Israeli Securities Law, consisting primarily of joint investment in trust funds, provident funds, insurance
companies, banks, portfolio managers, investment advisors, members of the Tel Aviv Stock Exchange, underwriter, venture capital funds, entities with equity in excess of NIS 50&nbsp;million and &#147;qualified individuals,&#148; each as defined in
the Addendum (as it may be amended from time to time), collectively referred to as qualified investors (in each case, purchasing for their own account or, where permitted under the Addendum, for the accounts of their clients who are investors listed
in the Addendum). Qualified investors are required to submit written confirmation that they fall within the scope of the Addendum, are aware of the meaning of same and agree to it. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Notice to Prospective Investors in Japan</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The offering has not been
and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948 of Japan, as amended) (<I>FIEL</I>), and the Initial Purchaser will not offer or sell any Securities, directly or indirectly, in Japan or
to, or for the benefit of, any resident of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others for
<FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance
with, the FIEL and any other applicable laws, regulations and ministerial guidelines of Japan. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Notice to Prospective Investors in Singapore</I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus supplement has not been and will not be lodged or registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus
supplement and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the Securities may not be circulated or distributed, nor may the Securities be offered or sold, or be made the subject
of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor under Section&nbsp;274 of the Securities and Futures Act, Chapter 289 of Singapore (the
<I>SFA</I>), (ii) to a relevant person pursuant to Section&nbsp;275(1), or any person pursuant to Section&nbsp;275(1A), and in accordance with the conditions </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
specified in Section&nbsp;275, of the SFA, or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA.</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Where the Securities are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is:</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of
which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary
of the trust is an individual who is an accredited investor, securities (as defined in Section&nbsp;239(1) of the SFA) of that corporation or the beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred
within six months after that corporation or that trust has acquired Securities pursuant to an offer made under Section&nbsp;275 of the SFA except: </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">to an institutional investor or to a relevant person defined in Section&nbsp;275(2) of the SFA, or to any person arising
from an offer referred to in Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">where no consideration is or will be given for the transfer; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">where the transfer is by operation of law; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">as specified in Section&nbsp;276(7) of the SFA; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations
2005 of Singapore. </P></TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Notice to Prospective Investors in the United Kingdom</I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No Securities have been offered or will be offered pursuant to the offering to the public in the United Kingdom prior to the publication of a prospectus in relation to
the Securities which has been approved by the Financial Conduct Authority, except that the Securities may be offered to the public in the United Kingdom at any time:</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">to any legal entity which is a &#147;qualified investor&#148; as defined under Article 2 of the UK Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the UK Prospectus
Regulation), subject to obtaining the prior consent of the Representative; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">in any other circumstances falling within Section&nbsp;86 of the Financial Services and Market Act 2000 (the <I>FSMA</I>),
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">provided that no such offer of the Securities shall require the Company or the underwriter to publish a prospectus pursuant to Section&nbsp;85 of
the FSMA, or supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation.</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the purposes of this provision, the expression an &#147;offer to
the public&#148; in relation to any Securities in the United&nbsp;Kingdom means the communication in any form and by any means of sufficient information on the terms of the offer and any Securities to be offered so as to enable an investor to decide
to purchase or subscribe for any Securities, and the expression &#147;UK Prospectus Regulation&#148; means Regulation (EU) 2017/1129 as it forms part of the domestic law by virtue of the European Union (Withdrawal) Act 2018. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, in the United Kingdom, this document is being distributed only to, and is directly only at, and any offer subsequently made may only be directed at persons
who are &#147;qualified investors&#148; (as defined in Article 2 of the UK Prospectus Regulation)&nbsp;(i) who have professional experience in matters relating to investments and who qualify as investment professionals within the meaning of Article
19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended, or the Financial Promotion Order; and/or (ii)&nbsp;who are high net worth companies (or persons to whom it may otherwise be lawfully communicated)
falling within Article 49(2)(a) to (d)&nbsp;of the Financial Promotion Order (all such persons together being referred to as &#147;relevant persons&#148;) or otherwise in circumstances which have not resulted and will not result in an offer to the
public of the Securities in the United&nbsp;Kingdom within the meaning of the FSMA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Notice to Prospective Investors in Switzerland </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The offering of the Securities in Switzerland is exempt from requirement to prepare and publish a prospectus under the Swiss Financial Services Act (&#147;FinSA&#148;)
because such offering is made to professional clients within the meaning of the FinSA only and the Securities will not be admitted to trading on any trading venue (exchange or multilateral trading facility) in Switzerland. This prospectus supplement
does not constitute a prospectus pursuant to the FinSA, and no such prospectus has been or will be prepared for or in connection with the offering of the Securities. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Notice to Prospective Investors in the United Arab Emirates </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This
prospectus supplement is strictly private and confidential and is being distributed to a limited number of Professional Investors, within the meaning of the United Arab Emirate&#146;s (the &#147;UAE&#148;) Securities and Commodities Authority&#146;s
(the &#147;SCA&#148;) Board of Directors Decision No.&nbsp;(13/Chairman) of 2021 on the Regulations Manual of the Financial Activities and Status Regularization Mechanisms Rule Book, and must not be provided to any person other than the original
recipient, and may not be reproduced or used for any other purpose. If you are in any doubt about the contents of this prospectus supplement, you should consult an authorized financial adviser. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">By receiving this prospectus supplement, the person or entity to whom it has been issued understands, acknowledges and agrees that this prospectus supplement has not
been approved by or filed with the UAE Central Bank, the SCA or any other authorities in the UAE, nor have the Joint Bookrunners received authorization or licensing from the UAE Central Bank, the SCA or any other authorities in the UAE to market or
sell securities or other investments within the UAE. No marketing of any financial products or services has been or will be made from within the UAE other than in compliance with the laws of the UAE and no subscription to any securities or other
investments may or will be consummated within the UAE. It should not be assumed that any of the Joint Bookrunners is a licensed broker, dealer or investment adviser under the laws applicable in the UAE, or that any of them advise individuals
resident in the UAE as to the appropriateness of investing in or purchasing or selling securities or other financial products. The Securities offered pursuant to this prospectus supplement may not be offered or sold directly or indirectly to the
public in the UAE and do not constitute a public offer of securities in the UAE in accordance with Federal Decree No.&nbsp;32 of 2021 on Commercial Companies or otherwise. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Notice to Prospective Investors in Australia </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus
supplement is not a disclosure document for the purposes of Australia&#146;s Corporations Act 2001 (Cth) of Australia, or Corporations Act, has not been lodged with the Australian Securities&nbsp;&amp; Investments Commission and is only directed to
the categories of exempt persons set out below. Accordingly, if you receive this prospectus supplement in Australia: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">You confirm and warrant that you are either: </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a &#147;sophisticated investor&#148; under section 708(8)(a) or (b)&nbsp;of the Corporations Act; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a &#147;sophisticated investor&#148; under section 708(8)(c) or (d)&nbsp;of the Corporations Act and that you have
provided an accountant&#146;s certificate to the Company which complies with the requirements of section; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">708(8)(c)(i) or (ii)&nbsp;of the Corporations Act and related regulations before the offer has been made;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a person associated with the Company under Section&nbsp;708(12) of the Corporations Act; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">a &#147;professional investor&#148; within the meaning of section 708(11)(a) or (b)&nbsp;of the Corporations Act.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To the extent that you are unable to confirm or warrant that you are an exempt sophisticated investor, associated person or professional investor
under the Corporations Act any offer made to you under this prospectus supplement is void and incapable of acceptance. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">You warrant and agree that you will not offer any of the securities issued to you pursuant to this prospectus supplement
for resale in Australia within 12 months of those securities being issued unless any such resale offer is exempt from the requirement to issue a disclosure document under section 708 of the Corporations Act. </P></TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Notice to Prospective Investors in Bermuda </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Securities may be offered
or sold in Bermuda only in compliance with the provisions of the Investment </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Business Act of 2003 of Bermuda which regulates the sale of securities in Bermuda.
Additionally, <FONT STYLE="white-space:nowrap">non-Bermudian</FONT> persons (including companies) may not carry on or engage in any trade or business in Bermuda unless such persons are permitted to do so under applicable Bermuda legislation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Notice to Prospective Investors in Saudi Arabia </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This document may not be distributed in the Kingdom of Saudi Arabia except to such persons as are permitted under the Offers of Securities Regulations as issued by the
board of the Saudi Arabian Capital Market Authority, or CMA, pursuant to resolution number <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2-11-2004</FONT></FONT> dated 4&nbsp;October 2004 as amended by resolution <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">number&nbsp;1-28-2008,</FONT></FONT> as amended. The CMA does not make any representation as to the accuracy or completeness of this document and expressly disclaims any liability
whatsoever for any loss arising from, or incurred in reliance upon, any part of this document. Prospective purchasers of the securities offered hereby should conduct their own due diligence on the accuracy of the information relating to the
securities. If you do not understand the contents of this document, you should consult an authorized financial adviser. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Notice to Prospective Investors in
China </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus supplement will not be circulated or distributed in the People&#146;s Republic of China, or the PRC, and the Securities will not be
offered or sold, and will not be offered or sold to any person for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale directly or indirectly to any residents of the PRC except pursuant to any applicable laws and regulations of the PRC.
Neither this prospectus supplement nor any advertisement or other offering material may be distributed or published in the PRC, except under circumstances that will result in compliance with applicable laws and regulations. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Notice to Prospective Investors in Taiwan </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Securities have not
been and will not be registered with the Financial Supervisory Commission of Taiwan pursuant to relevant securities laws and regulations and may not be sold, issued or offered within Taiwan through a public offering or in circumstances which
constitutes an offer within the meaning of the Securities and Exchange Act of Taiwan that requires a registration or approval of the Financial Supervisory Commission of Taiwan. No person or entity in Taiwan has been authorized to offer, sell, give
advice regarding or otherwise intermediate the offering and sale of the Securities in Taiwan. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Notice to Prospective Investors in Korea </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Securities have not been and will not be registered under the Financial Investments Services and Capital Markets Act of Korea and the decrees and regulations
thereunder, or the FSCMA, and the Securities have been and will be offered in Korea as a private placement under the FSCMA. None of the Securities may be offered, sold or delivered directly or indirectly, or offered or sold to any person for <FONT
STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Korea or to any resident of Korea except pursuant to the applicable laws and regulations of Korea, including the FSCMA and the Foreign Exchange Transaction Law of
Korea and the decrees and regulations thereunder, or the FETL. The Securities have not been listed on any securities exchanges in the world including, without limitation, the Korea Exchange in Korea. Furthermore, the purchaser of the Securities
shall comply with all applicable regulatory requirements (including but not limited to requirements under the FETL) in connection with the purchase of the Securities. By the purchase of the Securities, the relevant holder thereof will be deemed to
represent and warrant that if it is in Korea or is a resident of Korea, it purchased the Securities pursuant to the applicable laws and regulations of Korea. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Notice to Prospective Investors in Malaysia </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No prospectus or other
offering material or document in connection with the offer and sale of the Securities has been or will be registered with the Securities Commission of Malaysia, or the Commission, for the Commission&#146;s approval pursuant to the Capital Markets
and Services Act 2007. Accordingly, this prospectus supplement and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the Securities may not be circulated or distributed, nor may the
Securities be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Malaysia other than (i)&nbsp;a closed end fund approved by the Commission; (ii)&nbsp;a holder of a
Capital Markets Services Licence; (iii)&nbsp;a person who acquires the Securities, as principal, if the offer is on terms that the Securities may only be acquired at a consideration of not less than RM250,000 (or its equivalent in foreign
currencies) for each transaction; (iv)&nbsp;an individual whose total net personal assets or total net joint assets with his or her spouse exceeds RM3&nbsp;million (or its equivalent in foreign currencies), excluding the value of the primary
residence of the individual; (v)&nbsp;an individual who has a gross annual income exceeding RM300,000 (or its equivalent in foreign currencies) per annum in the preceding twelve months; (vi)&nbsp;an individual who, jointly with his or her spouse,
has a gross annual income of RM400,000 (or its equivalent in foreign currencies), per annum in the preceding twelve months; (vii)&nbsp;a corporation with total net assets exceeding RM10&nbsp;million (or its equivalent in a foreign currencies) based
on the last audited </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
accounts; (viii)&nbsp;a partnership with total net assets exceeding RM10&nbsp;million (or its equivalent in foreign currencies); (ix) a bank licensee or insurance licensee as defined in the
Labuan Financial Services and Securities Act 2010; (x) an Islamic bank licensee or takaful licensee as defined in the Labuan Financial Services and Securities Act 2010; and (xi)&nbsp;any other person as may be specified by the Commission; provided
that, in the each of the preceding categories (i)&nbsp;to (xi), the distribution of the Securities is made by a holder of a Capital Markets Services Licence who carries on the business of dealing in securities. The distribution in Malaysia of this
prospectus supplement is subject to Malaysian laws. This prospectus supplement does not constitute and may not be used for the purpose of public offering or an issue, offer for subscription or purchase, invitation to subscribe for or purchase any
securities requiring the registration of a prospectus with the Commission under the Capital Markets and Services Act 2007. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Notice to Prospective Investors in
South Africa </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Due to restrictions under the securities laws of South Africa, no &#147;offer to the public&#148; (as such term is defined in the South
African Companies Act, No.&nbsp;71 of 2008 (as amended or <FONT STYLE="white-space:nowrap">re-enacted),</FONT> or the South African Companies Act), is being made in connection with the issue of the Securities in South Africa. Accordingly, this
document does not, nor is it intended to, constitute a &#147;registered prospectus&#148; (as that term is defined in the South African Companies Act) prepared and registered under the South African Companies Act and has not been approved by, and/or
filed with, the South African Companies and Intellectual Property Commission or any other regulatory authority in South Africa. The Securities are not offered, and the offer shall not be transferred, sold, renounced or delivered, in South Africa or
to a person with an address in South Africa, unless one or other of the following exemptions stipulated in section 96 (1) applies: </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Section&nbsp;96 (1) (a) The
offer, transfer, sale, renunciation or delivery is to: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">persons whose ordinary business, or part of whose ordinary business, is to deal in securities, as principal or agent;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">the South African Public Investment Corporation; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">persons or entities regulated by the Reserve Bank of South Africa; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">authorised financial service providers under South African law; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">financial institutions recognised as such under South African law; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">a wholly-owned subsidiary of any person or entity contemplated in (c), (d) or (e), acting as agent in the capacity of an
authorised portfolio manager for a pension fund, or as manager for a collective investment scheme (in each case duly registered as such under South African law); or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">any combination of the person in (i)&nbsp;to (vi); or </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Section&nbsp;96 (1) (b) the total contemplated acquisition cost of the securities, for any single addressee acting as principal is equal to or greater than ZAR1,000,000
or such higher amount as may be promulgated by notice in the Government Gazette of South Africa pursuant to section 96(2)(a) of the South African Companies Act. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Information made available in this prospectus supplement should not be considered as &#147;advice&#148; as defined in the South African Financial Advisory and
Intermediary Services Act, 2002. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Notice to Prospective Investors in the British Virgin Islands </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Securities are not being, and may not be offered to the public or to any person in the British Virgin Islands for purchase or subscription by or on behalf of the
Company. The Securities may be offered to companies incorporated under the BVI Business Companies Act, 2004 (British Virgin Islands), or the BVI Companies, but only where the offer will be made to, and received by, the relevant BVI Company entirely
outside of the British Virgin Islands. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="supptoc446052_13"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The validity of the issuance of the securities offered in this prospectus supplement will be passed upon for us by Cooley LLP, New York, New York. The underwriters are
being represented in connection with this offering by Latham&nbsp;&amp; Watkins LLP, New York, New York. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="supptoc446052_14"></A>EXPERTS
</B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The consolidated financial statements of Annexon, Inc. as of December 31, 2022 and 2021, and for each of the years in the two-year period ended December 31,
2022, have been incorporated by reference herein and in the registration statement in reliance upon the report of KPMG LLP, independent registered public accounting firm, incorporated by reference herein, and upon the authority of said firm as
experts in accounting and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="supptoc446052_15"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File
<FONT STYLE="white-space:nowrap">No.&nbsp;333-258863)</FONT> under the Securities Act, of which this prospectus supplement forms a part. The rules and regulations of the SEC allow us to omit from this prospectus supplement and the accompanying
prospectus certain information included in the registration statement. For further information about us and the securities we are offering under this prospectus supplement and the accompanying prospectus, you should refer to the registration
statement and the exhibits and schedules filed with the registration statement. With respect to the statements contained in this prospectus supplement and the accompanying prospectus regarding the contents of any agreement or any other document, in
each instance, the statement is qualified in all respects by the complete text of the agreement or document, a copy of which has been filed as an exhibit to the registration statement. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We file reports, proxy statements and other information with the SEC under the Exchange Act. The SEC maintains an Internet website that contains reports, proxy
statements and other information about issuers, like us, that file electronically with the SEC. The address of that website is http://www.sec.gov. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Information
about us is also available at our website at http://www.annexonbio.com. Information contained on, or accessible through, our website shall not be deemed incorporated into and is not a part of this prospectus supplement or the registration statement
of which it forms a part. We have included our website in this prospectus supplement solely as an inactive textual reference. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="supptoc446052_16">
</A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The SEC&#146;s rules allow us to &#147;incorporate by reference&#148; information into this prospectus
supplement, which means that we can disclose important information to you by referring you to another document filed separately with the SEC. The information incorporated by reference is deemed to be part of this prospectus supplement, and
subsequent information that we file with the SEC will automatically update and supersede that information. Any statement contained in this prospectus supplement or a previously filed document incorporated by reference will be deemed to be modified
or superseded for purposes of this prospectus supplement to the extent that a statement contained in this prospectus supplement or a subsequently filed document incorporated by reference modifies or replaces that statement. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus supplement incorporates by reference the documents set forth below that have previously been filed with the SEC: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1528115/000095017023006232/annx-20221231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the year ended December&nbsp;31, 2022, filed with the SEC on March&nbsp;6, 2023; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the information specifically incorporated by reference into our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1528115/000095017023006232/annx-20221231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the year ended December&nbsp;31, 2022 from our Definitive Proxy Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1528115/000114036123020189/ny20007681x1_def14a.htm">Schedule 14A</A>,
filed with the SEC on April&nbsp;25, 2023; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarters ended <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1528115/000095017023018797/annx-20230331.htm">March&nbsp;31,
 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1528115/000095017023039054/annx-20230630.htm">June&nbsp;
30, 2023</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1528115/000095017023062913/annx-20230930.htm">September&nbsp;30, 2023</A>, filed with the SEC on May&nbsp;8, 2023, August&nbsp;7, 2023 and
November&nbsp;13, 2023, respectively; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (other than information furnished rather than
filed), filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1528115/000119312523002932/d426219d8k.htm">January&nbsp;
6, 2023</A> (other than Items 7.01 and 9.01), <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1528115/000119312523004050/d422908d8k.htm">January&nbsp;
9, 2023</A> (other than Items 7.01 and 9.01), <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1528115/000119312523067918/d462103d8k.htm">March&nbsp;
13, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1528115/000119312523153420/d468662d8k.htm">May&nbsp;
25, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1528115/000119312523164462/d510560d8k.htm">June&nbsp;
9, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1528115/000119312523199158/d418528d8k.htm">July&nbsp;
31, 2023</A> (other than Items 7.01 and 9.01), <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1528115/000119312523254189/d568195d8k.htm">October&nbsp;
11, 2023</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1528115/000119312523261704/d482545d8k.htm">October&nbsp;
24, 2023</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1528115/000119312523300035/d649765d8k.htm">December&nbsp;20, 2023</A> (other than Items 7.01 and 9.01); and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">the description of our common stock which is registered under Section&nbsp;12 of the Exchange Act, in our registration
statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1528115/000119312520196463/d90014d8a12b.htm">Form <FONT STYLE="white-space:nowrap">8-A</FONT></A>, filed on July&nbsp;21, 2020, including any amendment or reports filed for the purposes of
updating this description, including <A HREF="http://www.sec.gov/Archives/edgar/data/1528115/000156459022008044/annx-ex43_9.htm">Exhibit 4.3</A> to our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended
December&nbsp;31, 2022, filed with the SEC on March&nbsp;6, 2023. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All reports and other documents we subsequently file pursuant to
Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the termination of this offering, including all such documents we may file with the SEC after the date of the initial registration statement and prior to the effectiveness of the
registration statement, but excluding any information furnished to, rather than filed with, the SEC, will also be incorporated by reference into this prospectus supplement and deemed to be part of this prospectus supplement from the date of the
filing of such reports and documents. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">You may request a free copy of any of the documents incorporated by reference in this prospectus supplement by writing or
telephoning us at the following address: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Annexon, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">1400 Sierra Point Parkway, Bldg C, Suite 200 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Brisbane, California 94005 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(650) <FONT
STYLE="white-space:nowrap">822-5500</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Attention: Investor Relations </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Exhibits to the filings will not be sent, however, unless those exhibits have specifically been incorporated by reference in this prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">S-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g446052g01a02.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>ANNEXON, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>$300,000,000 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common
Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Preferred Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Debt Securities </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Units </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may offer and sell up to
$300,000,000 in the aggregate of the securities identified above from time to time in one or more offerings. This prospectus provides you with a general description of the securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each time we offer and sell securities, we will provide a supplement to this prospectus that contains specific information about the offering and the amounts,
prices and terms of the securities. The supplement may also add, update or change information contained in this prospectus with respect to that offering. You should carefully read this prospectus and the applicable prospectus supplement before you
invest in any of our securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may offer and sell the securities described in this prospectus and any prospectus supplement to or through one or
more underwriters, dealers and agents, or directly to purchasers, or through a combination of these methods. If any underwriters, dealers or agents are involved in the sale of any of the securities, their names and any applicable purchase price,
fee, commission or discount arrangement between or among them will be set forth, or will be calculable from the information set forth, in the applicable prospectus supplement. See the sections of this prospectus titled &#147;About this
Prospectus&#148; and &#147;Plan of Distribution&#148; for more information. No securities may be sold without delivery of this prospectus and the applicable prospectus supplement describing the method and terms of the offering of such securities.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>INVESTING IN OUR SECURITIES INVOLVES RISKS. SEE THE &#147;<A HREF="#toca446052_4">RISK FACTORS</A>&#148; ON PAGE&nbsp;5 OF THIS PROSPECTUS AND ANY
SIMILAR SECTION CONTAINED IN THE APPLICABLE PROSPECTUS SUPPLEMENT CONCERNING FACTORS YOU SHOULD CONSIDER BEFORE INVESTING IN OUR SECURITIES. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
common stock is listed on the Nasdaq Global Select Market under the symbol &#147;ANNX.&#148; On February&nbsp;28, 2022, the last reported sale price of our common stock on the Nasdaq Global Select Market was $4.855 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the
adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is
May 3, 2022. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">Page</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca446052_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca446052_2">WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION BY
REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca446052_3">THE COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca446052_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca446052_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca446052_6">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca446052_7">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca446052_8">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca446052_9">DESCRIPTION OF UNITS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca446052_10">GLOBAL SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca446052_11">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca446052_12">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#toca446052_13">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca446052_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, or the SEC using a &#147;shelf&#148;
registration process. By using a shelf registration statement, we may sell securities from time to time and in one or more offerings up to a total dollar amount of $300,000,000 as described in this prospectus. Each time that we offer and sell
securities, we will provide a prospectus supplement to this prospectus that contains specific information about the securities being offered and sold and the specific terms of that offering. We may also authorize one or more free writing
prospectuses to be provided to you that may contain material information relating to these offerings. The prospectus supplement or free writing prospectus may also add, update or change information contained in this prospectus with respect to that
offering. If there is any inconsistency between the information in this prospectus and the applicable prospectus supplement or free writing prospectus, you should rely on the prospectus supplement or free writing prospectus, as applicable. Before
purchasing any securities, you should carefully read both this prospectus and the applicable prospectus supplement (and any applicable free writing prospectuses), together with the additional information described under the heading &#147;Where You
Can Find More Information; Incorporation by Reference.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not authorized anyone to provide you with any information or to make any
representations other than those contained in this prospectus, any applicable prospectus supplement or any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no
assurance as to the reliability of, any other information that others may give you. We will not make an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in
this prospectus and the applicable prospectus supplement to this prospectus is accurate only as of the date on its respective cover, that the information appearing in any applicable free writing prospectus is accurate only as of the date of that
free writing prospectus, and that any information incorporated by reference is accurate only as of the date of the document incorporated by reference, unless we indicate otherwise. Our business, financial condition, results of operations and
prospects may have changed since those dates. This prospectus incorporates by reference, and any prospectus supplement or free writing prospectus may contain and incorporate by reference, market data and industry statistics and forecasts that are
based on independent industry publications and other publicly available information. Although we believe these sources are reliable, we do not guarantee the accuracy or completeness of this information and we have not independently verified this
information. In addition, the market and industry data and forecasts that may be included or incorporated by reference in this prospectus, any prospectus supplement or any applicable free writing prospectus may involve estimates, assumptions and
other risks and uncertainties and are subject to change based on various factors, including those discussed under the heading &#147;Risk Factors&#148; contained in this prospectus, the applicable prospectus supplement and any applicable free writing
prospectus, and under similar headings in other documents that are incorporated by reference into this prospectus. Accordingly, investors should not place undue reliance on this information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When we refer to &#147;Annexon,&#148; &#147;we,&#148; &#147;our,&#148; &#147;us&#148; and the &#147;Company&#148; in this prospectus, we mean Annexon, Inc.
and its consolidated subsidiary, unless otherwise specified. When we refer to &#147;you,&#148; we mean the potential holders of the applicable series of securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca446052_2"></A>WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION BY REFERENCE
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Available Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We file reports, proxy
statements and other information with the SEC. The SEC maintains a website that contains reports, proxy and information statements and other information about issuers, such as us, who file electronically with the SEC. The address of that website is
<I>http://www.sec.gov</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our corporate website address is www.annexonbio.com. The information on our website, however, is not, and should not be deemed
to be, a part of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus and any prospectus supplement are part of a registration statement that we filed with the SEC and do
not contain all of the information in the registration statement. The full registration statement may be obtained from the SEC or us, as provided below. Forms of the indenture and other documents establishing the terms of the offered securities are
or may be filed as exhibits to the registration statement or documents incorporated by reference in the registration statement. Statements in this prospectus or any prospectus supplement or any related free writing prospectus that we may provide
about these documents are summaries and each statement is qualified in all respects by reference to the document to which it refers. You should refer to the actual documents for a more complete description of the relevant matters. You may inspect a
copy of the registration statement through the SEC&#146;s website, as provided above. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Incorporation by Reference </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC&#146;s rules allow us to &#147;incorporate by reference&#148; information into this prospectus, which means that we can disclose important information
to you by referring you to another document filed separately with the SEC. The information incorporated by reference is deemed to be part of this prospectus, and subsequent information that we file with the SEC will automatically update and
supersede that information. Any statement contained in this prospectus or a previously filed document incorporated by reference will be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in
this prospectus, the related prospectus supplement or any free writing prospectus that we may provide or any subsequently filed document incorporated by reference modifies or replaces that statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus and any accompanying prospectus supplement incorporate by reference the documents set forth below that have previously been filed with the
SEC: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001528115/000156459022008044/annx-10k_20211231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the year ended December&nbsp;31, 2021, filed with the SEC on March&nbsp;1, 2022; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The information specifically incorporated by reference into our Annual Report on Form 10-K for the year ended
December 31, 2020 from our <A HREF="http://www.sec.gov/Archives/edgar/data/1528115/000119312521126685/d140960ddef14a.htm">Definitive Proxy Statement</A> on Schedule 14A, filed with the SEC on April 22, 2021; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> (other than information furnished rather
than filed), filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1528115/000119312522001705/d283972d8k.htm">January&nbsp;
4, 2022</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1528115/000119312522013774/d477760d8k.htm">January&nbsp;
20, 2022</A> (other than Items 7.01 and 9.01), <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1528115/000119312522026977/d303262d8k.htm">February&nbsp;
3, 2022</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1528115/000119312522048725/d309530d8k.htm">February 22, 2022</A>; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">The description of our common stock, which is registered under Section&nbsp;12 of the Securities Exchange Act of
1934, as amended, which we refer to as the &#147;Exchange Act&#148; in this prospectus, in our registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1528115/000119312520196463/d90014d8a12b.htm">Form <FONT STYLE="white-space:nowrap">8-A
</FONT></A>, filed on July&nbsp;21, 2020 and any amendment or reports filed for the purposes of updating the description. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All reports
and other documents we subsequently file pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the termination of this offering, but excluding any information furnished to, rather than filed with, the SEC, will also be
incorporated by reference into this prospectus and deemed to be part of this prospectus from the date of the filing of such reports and documents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may request a free copy of any of the documents incorporated by reference in this prospectus by writing
or telephoning us at the following address: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Annexon, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1400 Sierra Point Parkway, Bldg C, Suite 200 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Brisbane, California 94005 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(650) <FONT
STYLE="white-space:nowrap">822-5500</FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention: Investor Relations </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Exhibits to the filings will not be sent, however, unless those exhibits have specifically been incorporated by reference in this prospectus or any
accompanying prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca446052_3"></A>THE COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical company pioneering a new class of complement medicines designed to stop the classical complement pathway at its
start, C1q, in order to bring therapies to patients suffering from serious complement-mediated autoimmune, neurodegenerative and ophthalmic disorders. C1q, the initiating molecule of the classical complement pathway, is a core component to the
body&#146;s immune system that activates a powerful inflammatory cascade. We believe that by stopping the classical complement pathway at its start, our approach may have the potential to provide more complete protection against complement-mediated
disorders of the body, brain and eye. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our proprietary platform leverages well-researched classical complement-mediated autoimmune and neurodegenerative
disease processes, both of which are triggered by aberrant activation of C1q. Evidence suggests that potent and selective inhibition of C1q can prevent tissue damage triggered in antibody-mediated autoimmune disease and preserve loss of functioning
synapses associated with cognitive and functional decline in complement-mediated neurodegeneration. By taking an upstream complement approach targeting C1q, our treatments are designed to act as an &#147;on/off switch&#148; to block all downstream
components of the classical complement pathway that lead to excess inflammation, tissue damage and patient disability in a host of complement-mediated disorders, while preserving the normal immune function of the lectin and alternative complement
pathways involved in the clearance of pathogens and damaged cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were incorporated under the laws of the State of Delaware on March&nbsp;3, 2011.
Our principal executive offices are located at 1400 Sierra Point Parkway, Bldg C, Suite 200, Brisbane, California 94005, and our telephone number is (650) <FONT STYLE="white-space:nowrap">822-5500.</FONT> Our corporate website address is
www.annexonbio.com. Information contained on, or accessible through, our website shall not be deemed incorporated into and is not a part of this prospectus or the registration statement of which it forms a part. We have included our website in this
prospectus solely as an inactive textual reference. Because (i)&nbsp;the aggregate worldwide market value of our voting common stock held by <FONT STYLE="white-space:nowrap">non-affiliates,</FONT> or public float, exceeded $700&nbsp;million on
June&nbsp;30, 2021, (ii) we had been subject to the reporting requirements of Section&nbsp;13(a) or 15(d) of the Exchange Act for at least twelve calendar months, (iii)&nbsp;we had previously filed an annual report under Section&nbsp;13(a) or 15(d)
of the Exchange Act and (iv)&nbsp;we were not eligible for smaller reporting company status because we exceed the public float and revenue threshold for such status, we qualified as a &#147;large accelerated filer&#148; under Rule <FONT
STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act as of the end of the 2021 fiscal year. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca446052_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investment in any securities offered pursuant to this prospectus and the applicable prospectus supplement involves risks. You should carefully consider the
risk factors included in our most recent Annual Report on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K,</FONT> our most recent Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and any subsequent Annual Reports on <FONT
STYLE="white-space:nowrap">Form&nbsp;10-K,</FONT> Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> or Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> we file after the date of this prospectus, and all other
information contained or incorporated by reference into this prospectus, as updated by our subsequent filings under the Exchange Act, and the risk factors and other information contained in the applicable prospectus supplement and any applicable
free writing prospectus before acquiring any of such securities. The occurrence of any of these risks might cause you to lose all or part of your investment in the offered securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca446052_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds from the sale of the securities as set forth in the applicable prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca446052_6"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>The following summary describes our capital stock and the material provisions of our amended and restated certificate of incorporation and our amended and
restated bylaws, the amended and restated investors&#146; rights agreement to which we and certain of our stockholders are parties and of the Delaware General Corporation Law. Because the following is only a summary, it does not contain all of the
information that may be important to you. For a complete description, you should refer to our amended and restated certificate of incorporation, amended and restated bylaws and amended and restated investors&#146; rights agreement, copies of which
have been filed as exhibits to the registration statement of which this prospectus is part. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our authorized capital stock consists of&nbsp;300,000,000&nbsp;shares of common stock, par value $0.001 per share, and 5,000,000&nbsp;shares of preferred
stock, par value $0.001 per share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Voting Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each holder of common stock is
entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of directors. The election of directors by our stockholders shall be determined by a plurality of the votes cast and our stockholders
do not have cumulative voting rights in the election of directors. Other matters shall be generally decided by the affirmative vote of the holders of a majority of the votes cast (excluding abstentions and broker
<FONT STYLE="white-space:nowrap">non-votes)</FONT> on such matter. In addition, the affirmative vote of holders of 66 2/3% of the voting power of all of the then outstanding voting stock will be required to take certain actions, including amending
certain provisions of our amended and restated certificate of incorporation, including the provisions relating to amending our amended and restated bylaws, the classified board and director liability. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Dividends </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to preferences that may be
applicable to any then outstanding preferred stock, holders of our common stock are entitled to receive dividends as may be declared from time to time by our board of directors out of legally available funds. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Liquidation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of our liquidation,
dissolution or winding up, holders of our common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities, subject to the satisfaction of
any liquidation preference granted to the holders of any then outstanding shares of preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Rights and Preferences </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of our common stock have no preemptive, conversion or subscription rights, and there are no redemption or sinking fund provisions applicable to our
common stock. The rights, preferences and privileges of the holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of our preferred stock that we may designate and issue in the
future. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Fully Paid and Nonassessable </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All of
our outstanding shares of common stock are fully paid and nonassessable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors has the authority, without further action by our stockholders, to issue up to&nbsp;5,000,000&nbsp;shares of preferred stock in one or
more series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund
terms and the number of shares constituting, or the designation of, such series, any or all of which may be greater than the rights of our common stock. The issuance of our preferred stock could adversely affect the voting power of holders of common
stock and the likelihood that such holders will receive dividend payments and payments upon our liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of our company
or other corporate action. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under our amended and restated investors&#146; rights agreement, certain holders of shares of our common stock, or their transferees, have the right to require
us to register their shares under the Securities Act so that those shares may be publicly resold, and certain holders of shares of our common stock, or their transferees, have the right to include their shares in any registration statement we file,
in each case as described below.</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Demand Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain holders of shares of our common stock are entitled to certain demand registration rights. The holders of at least 60% of such registrable securities
may, on not more than two occasions, request that we register all or a portion of their shares, subject to certain specified exceptions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Piggyback
Registration Rights </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that we propose to register any of our securities under the Securities Act, either for our own account or for the
account of other security holders, certain holders of registrable securities will be entitled to certain &#147;piggyback&#148; registration rights allowing them to include their shares in such registration, subject to specified conditions and
limitations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">S-3</FONT> Registration Rights </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain holders of shares of our common stock are entitled to certain <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> registration rights. The holders of
at least 30% of such registrable securities may, on not more than two registrations on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> within any <FONT STYLE="white-space:nowrap">12-month</FONT> period, request that we register all or a
portion of their shares on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> if we are qualified to file a registration statement on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> subject to specified exceptions. Such request for registration
on <FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> must cover securities with an aggregate offering price which equals or exceeds $1.0&nbsp;million, net of selling expenses. The right to have such shares registered on <FONT
STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> is further subject to other specified conditions and limitations. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Effects of Provisions
of Delaware Law and Our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certain provisions of Delaware law and our
amended and restated certificate of incorporation and our amended and restated bylaws contain provisions that could make the following transactions more difficult: acquisition of us by means of a tender offer; acquisition of us by means of a proxy
contest or otherwise; or removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best
interest or in our best interests, including transactions that might result in a premium over the market price for our shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These provisions, summarized below, are expected to discourage coercive takeover practices and inadequate
takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of increased protection of our potential ability to negotiate with
the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Delaware Anti-Takeover Statute </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to
Section&nbsp;203 of the Delaware General Corporation Law, which prohibits persons deemed &#147;interested stockholders&#148; from engaging in a &#147;business combination&#148; with a publicly-held Delaware corporation for three years following the
date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an
&#147;interested stockholder&#148; is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#146;s voting stock.
Generally, a &#147;business combination&#148; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect
to transactions not approved in advance by the board of directors, such as discouraging takeover attempts that might result in a premium over the market price of our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Undesignated Preferred Stock </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ability to
authorize undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to effect a change in control of our company. These
and other provisions may have the effect of deterring hostile takeovers or delaying changes in control or management of our company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Special
Stockholder Meetings </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation provide that a special meeting of stockholders may be called at any
time by our board of directors, but such special meetings may not be called by the stockholders or any other person or persons. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Requirements for
Advance Notification of Stockholder Nominations and Proposals </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and restated bylaws establish advance notice procedures with respect to
stockholder proposals and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stockholder Action by Written Consent </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended
and restated certificate of incorporation precludes stockholder action by written consent without a meeting. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Classified Board; Election and Removal
of Directors; Filling Vacancies </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors is divided into three classes, divided as nearly as equal in number as possible. The
directors in each class serve for a three-year term, one class being elected each year by our stockholders, with staggered three-year terms. Only one class of directors will be elected at each annual meeting of our stockholders, with the other
classes continuing for the remainder of their respective three-year terms. Because our stockholders do not have cumulative voting rights, our stockholders holding a majority of the shares of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
common stock outstanding will be able to elect all of our directors. Our amended and restated certificate of incorporation provides for the removal of any of our directors only for cause and
requires a stockholder vote by the holders of at least a 66 2/3% of the voting power of the then outstanding voting stock. Furthermore, any vacancy on our board of directors, however occurring, including a vacancy resulting from an increase in the
size of the board, may only be filled by a resolution of the board of directors unless the board of directors determines that such vacancies shall be filled by the stockholders. This system of electing and removing directors and filling vacancies
may tend to discourage a third party from making a tender offer or otherwise attempting to obtain control of us because it generally makes it more difficult for stockholders to replace a majority of the directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Choice of Forum </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and restated
certificate of incorporation and amended and restated bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the exclusive forum for the following types of
actions or proceedings under Delaware statutory or common law: any derivative action or proceeding brought on our behalf; any action asserting a claim of breach of fiduciary duty owed by any of our directors, officers or stockholders to us or to our
stockholders; any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended and restated certificate of incorporation or our amended and restated bylaws (as either may be amended from time to time); or
any action asserting a claim against us that is governed by the internal affairs doctrine. As a result, any action brought by any of our stockholders with regard to any of these matters will need to be filed in the Court of Chancery of the State of
Delaware and cannot be filed in any other jurisdiction; provided that, the exclusive forum provision will not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal courts have
exclusive jurisdiction; and provided further that, if and only if the Court of Chancery of the State of Delaware dismisses any such action for lack of subject matter jurisdiction, such action may be brought in another state or federal court sitting
in the State of Delaware. Our amended and restated certificate of incorporation and amended and restated bylaws also provide that the federal district courts of the United States of America will be the exclusive forum for the resolution of any
complaint asserting a cause of action against us or any of our directors, officers, employees or agents and arising under the Securities Act. Nothing in our amended and restated certificate of incorporation and amended and restated bylaws preclude
stockholders that assert claims under the Exchange Act from bringing such claims in state or federal court, subject to applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any action the
subject matter of which is within the scope described above is filed in a court other than a court located within the State of Delaware, or a Foreign Action, in the name of any stockholder, such stockholder shall be deemed to have consented to the
personal jurisdiction of the state and federal courts located within the State of Delaware in connection with any action brought in any such court to enforce the applicable provisions of our amended and restated certificate of incorporation and
amended and restated bylaws and having service of process made upon such stockholder in any such action by service upon such stockholder&#146;s counsel in the Foreign Action as agent for such stockholder. Although our amended and restated
certificate of incorporation and amended and restated bylaws contain the choice of forum provision described above, it is possible that a court could find that such a provision is inapplicable for a particular claim or action or that such provision
is unenforceable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This choice of forum provision may limit a stockholder&#146;s ability to bring a claim in a judicial forum that it finds favorable for
disputes with us or any of our directors, officers, other employees or stockholders, which may discourage lawsuits with respect to such claims, although our stockholders will not be deemed to have waived our compliance with federal securities laws
and the rules and regulations thereunder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Amendment of Charter Provisions </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amendment of any of the above provisions in our amended and restated certificate of incorporation, except for the provision making it possible for our
board of directors to issue undesignated preferred stock, requires approval by a stockholder vote by the holders of at least a 66 2/3% of the voting power of the then outstanding voting stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The provisions of the Delaware General Corporation Law, or the DGCL, our amended and restated certificate of
incorporation and our amended and restated bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market price of our common stock that often
result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in our management. It is possible that these provisions could make it more difficult to accomplish transactions that
stockholders may otherwise deem to be in their best interests. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitation on Liability and Indemnification </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and our amended and restated bylaws limit our directors&#146; liability, contain provisions that provide
that we may indemnify our directors and officers to the fullest extent permitted under the DGCL. The DGCL provides that directors of a corporation will not be personally liable for monetary damages for breach of their fiduciary duties as directors,
except for liability for any: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">transaction from which the director derives an improper personal benefit; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">unlawful payment of dividends or redemption of shares; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">breach of a director&#146;s duty of loyalty to the corporation or its stockholders. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These limitations of liability do not apply to liabilities arising under federal securities laws and do not affect the availability of equitable remedies such
as injunctive relief or recession. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The DGCL and our amended and restated bylaws provide that we will, in certain situations, indemnify our directors and
officers and may indemnify other employees and other agents, to the fullest extent permitted by law. Any indemnified person is also entitled, subject to certain limitations, to advancement, direct payment or reimbursement of reasonable expenses
(including attorneys&#146; fees and disbursements) in advance of the final disposition of the proceeding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we have entered, and intend to
continue to enter, into separate indemnification agreements with our directors and officers. These indemnification agreements, among other things, require us to indemnify our directors and officers for certain expenses, including attorneys&#146;
fees, judgments, fines and settlement amounts incurred by a director or officer in any action or proceeding arising out of their services as a director or officer, or any other company or enterprise to which the person provides services at our
request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also maintain a directors&#146; and officers&#146; insurance policy pursuant to which our directors and officers are insured against
liability for actions taken in their capacities as directors and officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that these provisions in our amended and restated certificate of
incorporation and amended and restated bylaws and these indemnification agreements are necessary to attract and retain qualified persons as directors and officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or control persons, in the opinion of the
SEC, such indemnification is against public policy, as expressed in the Securities Act and is therefore unenforceable. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our common stock is Computershare, Inc. The transfer agent and registrar&#146;s address is 462 South 4th Street,
Louisville, Kentucky 40202. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca446052_7"></A>DESCRIPTION OF DEBT SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following description, together with the additional information we include in any applicable prospectus supplement or free writing prospectus, summarizes
certain general terms and provisions of the debt securities that we may offer under this prospectus. When we offer to sell a particular series of debt securities, we will describe the specific terms of the series in a supplement to this prospectus.
We will also indicate in the supplement to what extent the general terms and provisions described in this prospectus apply to a particular series of debt securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue debt securities either separately, or together with, or upon the conversion or exercise of or in exchange for, other securities described in this
prospectus. Debt securities may be our senior, senior subordinated or subordinated obligations and, unless otherwise specified in a supplement to this prospectus, the debt securities will be our direct, unsecured obligations and may be issued in one
or more series. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The debt securities will be issued under an indenture between us and a third party to be identified therein, as trustee. We have
summarized select portions of the indenture below. The summary is not complete. The form of the indenture has been filed as an exhibit to the registration statement and you should read the indenture for provisions that may be important to you. In
the summary below, we have included references to the section numbers of the indenture so that you can easily locate these provisions. Capitalized terms used in the summary and not defined herein have the meanings specified in the indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As used in this section only, &#147;Annexon,&#148; &#147;we,&#148; &#147;our&#148; or &#147;us&#148; refer to Annexon, Inc. excluding our subsidiary, unless
expressly stated or the context otherwise requires. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The terms of each series of debt securities will be established by or pursuant to a resolution of our board of directors and set forth or determined in the
manner provided in a resolution of our board of directors, in an officer&#146;s certificate or by a supplemental indenture. (Section 2.2) The particular terms of each series of debt securities will be described in a prospectus supplement relating to
such series (including any pricing supplement or term sheet). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We can issue an unlimited amount of debt securities under the indenture that may be in one
or more series with the same or various maturities, at par, at a premium, or at a discount. (Section 2.1) We will set forth in a prospectus supplement (including any pricing supplement or term sheet) relating to any series of debt securities being
offered, the aggregate principal amount and the following terms of the debt securities, if applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title and ranking of the debt securities (including the terms of any subordination provisions);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price or prices (expressed as a percentage of the principal amount) at which we will sell the debt
securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any limit on the aggregate principal amount of the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date or dates on which the principal of the securities of the series is payable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate or rates (which may be fixed or variable) per annum or the method used to determine the rate or rates
(including any commodity, commodity index, stock exchange index or financial index) at which the debt securities will bear interest, the date or dates from which interest will accrue, the date or dates on which interest will commence and be payable
and any regular record date for the interest payable on any interest payment date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the place or places where principal of, and interest, if any, on the debt securities will be payable (and the
method of such payment), where the securities of such series may be surrendered for registration of transfer or exchange, and where notices and demands to us in respect of the debt securities may be delivered; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the period or periods within which, the price or prices at which and the terms and conditions upon which we may
redeem the debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any obligation we have to redeem or purchase the debt securities pursuant to any sinking fund or analogous
provisions or at the option of a holder of debt securities and the period or periods within which, the price or prices at which and in the terms and conditions upon which securities of the series shall be redeemed or purchased, in whole or in part,
pursuant to such obligation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dates on which and the price or prices at which we will repurchase debt securities at the option of the
holders of debt securities and other detailed terms and provisions of these repurchase obligations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the denominations in which the debt securities will be issued, if other than denominations of $1,000 and any
integral multiple thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities will be issued in the form of certificated debt securities or global debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the portion of principal amount of the debt securities payable upon declaration of acceleration of the maturity
date, if other than the principal amount; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency of denomination of the debt securities, which may be United States Dollars or any foreign currency,
and if such currency of denomination is a composite currency, the agency or organization, if any, responsible for overseeing such composite currency; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation of the currency, currencies or currency units in which payment of principal of, premium and
interest on the debt securities will be made; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if payments of principal of, premium or interest on the debt securities will be made in one or more currencies or
currency units other than that or those in which the debt securities are denominated, the manner in which the exchange rate with respect to these payments will be determined; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manner in which the amounts of payment of principal of, premium, if any, or interest on the debt securities
will be determined, if these amounts may be determined by reference to an index based on a currency or currencies or by reference to a commodity, commodity index, stock exchange index or financial index; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions relating to any security provided for the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any addition to, deletion of or change in the Events of Default described in this prospectus or in the indenture
with respect to the debt securities and any change in the acceleration provisions described in this prospectus or in the indenture with respect to the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any addition to, deletion of or change in the covenants described in this prospectus or in the indenture with
respect to the debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any depositaries, interest rate calculation agents, exchange rate calculation agents or other agents with respect
to the debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the provisions, if any, relating to conversion or exchange of any debt securities of such series, including if
applicable, the conversion or exchange price and period, provisions as to whether conversion or exchange will be mandatory, the events requiring an adjustment of the conversion or exchange price and provisions affecting conversion or exchange;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other terms of the debt securities, which may supplement, modify or delete any provision of the indenture as
it applies to that series, including any terms that may be required under applicable law or regulations or advisable in connection with the marketing of the securities; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether any of our direct or indirect subsidiaries will guarantee the debt securities of that series, including
the terms of subordination, if any, of such guarantees. (Section 2.2) </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue debt securities that provide for an amount less than their stated principal amount to be due
and payable upon declaration of acceleration of their maturity pursuant to the terms of the indenture. We will provide you with information on the federal income tax considerations and other special considerations applicable to any of these debt
securities in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we denominate the purchase price of any of the debt securities in a foreign currency or currencies
or a foreign currency unit or units, or if the principal of and any premium and interest on any series of debt securities is payable in a foreign currency or currencies or a foreign currency unit or units, we will provide you with information on the
restrictions, elections, general tax considerations, specific terms and other information with respect to that issue of debt securities and such foreign currency or currencies or foreign currency unit or units in the applicable prospectus
supplement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer and Exchange </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each debt
security will be represented by either one or more global securities registered in the name of The Depository Trust Company, or the Depositary, or a nominee of the Depositary (we will refer to any debt security represented by a global debt security
as a &#147;book-entry debt security&#148;), or a certificate issued in definitive registered form (we will refer to any debt security represented by a certificated security as a &#147;certificated debt security&#148;) as set forth in the applicable
prospectus supplement. Except as set forth under the heading &#147;Global Debt Securities and Book-Entry System&#148; below, book-entry debt securities will not be issuable in certificated form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certificated Debt Securities. You may transfer or exchange certificated debt securities at any office we maintain for this purpose in accordance with the
terms of the indenture. (Section 2.4) No service charge will be made for any transfer or exchange of certificated debt securities, but we may require payment of a sum sufficient to cover any tax or other governmental charge payable in connection
with a transfer or exchange. (Section 2.7) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may effect the transfer of certificated debt securities and the right to receive the principal of, premium
and interest on certificated debt securities only by surrendering the certificate representing those certificated debt securities and either reissuance by us or the trustee of the certificate to the new holder or the issuance by us or the trustee of
a new certificate to the new holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Global Debt Securities and Book-Entry System. Each global debt security representing book-entry debt securities will
be deposited with, or on behalf of, the Depositary, and registered in the name of the Depositary or a nominee of the Depositary. Please see &#147;Global Securities.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Covenants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will set forth in the applicable prospectus
supplement any restrictive covenants applicable to any issue of debt securities. (Article IV) </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Protection in the Event of a Change of Control
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless we state otherwise in the applicable prospectus supplement, the debt securities will not contain any provisions which may afford holders of the
debt securities protection in the event we have a change in control or in the event of a highly leveraged transaction (whether or not such transaction results in a change in control), which could adversely affect holders of debt securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidation, Merger and Sale of Assets </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not
consolidate with or merge with or into, or convey, transfer or lease all or substantially all of our properties and assets to any person (a &#147;successor person&#148;) unless: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are the surviving corporation or the successor person (if other than Annexon) is a corporation organized and
validly existing under the laws of any U.S. domestic jurisdiction and expressly assumes our obligations on the debt securities and under the indenture; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">immediately after giving effect to the transaction, no Default or Event of Default, shall have occurred and be
continuing. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the above, any of our subsidiaries may consolidate with, merge into or transfer all or part of its
properties to us. (Section 5.1) </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Events of Default </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Event of Default&#148; means with respect to any series of debt securities, any of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">default in the payment of any interest upon any debt security of that series when it becomes due and payable, and
continuance of such default for a period of 30 days (unless the entire amount of the payment is deposited by us with the trustee or with a paying agent prior to the expiration of the <FONT STYLE="white-space:nowrap">30-day</FONT> period);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">default in the payment of principal of any security of that series at its maturity; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">default in the performance or breach of any other covenant or warranty by us in the indenture (other than a
covenant or warranty that has been included in the indenture solely for the benefit of a series of debt securities other than that series), which default continues uncured for a period of 60 days after we receive written notice from the trustee or
Annexon and the trustee receive written notice from the holders of not less than 25% in principal amount of the outstanding debt securities of that series as provided in the indenture; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain voluntary or involuntary events of bankruptcy, insolvency or reorganization of Annexon; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other Event of Default provided with respect to debt securities of that series that is described in the
applicable prospectus supplement. (Section 6.1) </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No Event of Default with respect to a particular series of debt securities (except as
to certain events of bankruptcy, insolvency or reorganization) necessarily constitutes an Event of Default with respect to any other series of debt securities. (Section 6.1) The occurrence of certain Events of Default or an acceleration under the
indenture may constitute an event of default under certain indebtedness of ours or our subsidiaries outstanding from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will provide the
trustee written notice of any Default or Event of Default within 30 days of becoming aware of the occurrence of such Default or Event of Default, which notice will describe in reasonable detail the status of such Default or Event of Default and what
action we are taking or propose to take in respect thereof. (Section&nbsp;6.1) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an Event of Default with respect to debt securities of any series at
the time outstanding occurs and is continuing, then the trustee or the holders of not less than 25% in principal amount of the outstanding debt securities of that series may, by a notice in writing to us (and to the trustee if given by the holders),
declare to be due and payable immediately the principal of (or, if the debt securities of that series are discount securities, that portion of the principal amount as may be specified in the terms of that series) and accrued and unpaid interest, if
any, on all debt securities of that series. In the case of an Event of Default resulting from certain events of bankruptcy, insolvency or reorganization, the principal (or such specified amount) of and accrued and unpaid interest, if any, on all
outstanding debt securities will become and be immediately due and payable without any declaration or other act on the part of the trustee or any holder of outstanding debt securities. At any time after a declaration of acceleration with respect to
debt securities of any series has been made, but before a judgment or decree for payment of the money due has been obtained by the trustee, the holders of a majority in principal amount of the outstanding debt securities of that series may rescind
and annul the acceleration if all Events of Default, other than the <FONT STYLE="white-space:nowrap">non-payment</FONT> of accelerated principal and interest, if any, with respect to debt securities of that series, have been cured or waived as
provided in the indenture. (Section 6.2) We refer you to the prospectus </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
supplement relating to any series of debt securities that are discount securities for the particular provisions relating to acceleration of a portion of the principal amount of such discount
securities upon the occurrence of an Event of Default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The indenture provides that the trustee may refuse to perform any duty or exercise any of its
rights or powers under the indenture unless the trustee receives indemnity satisfactory to it against any cost, liability or expense which might be incurred by it in performing such duty or exercising such right or power. (Section 7.1(e)) Subject to
certain rights of the trustee, the holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the
trustee or exercising any trust or power conferred on the trustee with respect to the debt securities of that series. (Section 6.12) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No holder of any
debt security of any series will have any right to institute any proceeding, judicial or otherwise, with respect to the indenture or for the appointment of a receiver or trustee, or for any remedy under the indenture, unless: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that holder has previously given to the trustee written notice of a continuing Event of Default with respect to
debt securities of that series; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holders of not less than 25% in principal amount of the outstanding debt securities of that series have made
written request, and offered indemnity or security satisfactory to the trustee, to the trustee to institute the proceeding as trustee, and the trustee has not received from the holders of not less than a majority in principal amount of the
outstanding debt securities of that series a direction inconsistent with that request and has failed to institute the proceeding within 60 days. (Section 6.7) </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding any other provision in the indenture, the holder of any debt security will have an absolute and unconditional right to receive payment of the
principal of, premium and any interest on that debt security on or after the due dates expressed in that debt security and to institute suit for the enforcement of payment. (Section&nbsp;6.8) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The indenture requires us, within 120 days after the end of our fiscal year, to furnish to the trustee a statement as to compliance with the indenture.
(Section 4.3) If a Default or Event of Default occurs and is continuing with respect to the securities of any series and if it is known to a responsible officer of the trustee, the trustee shall mail to each Securityholder of the securities of that
series notice of a Default or Event of Default within 90 days after it occurs or, if later, after a responsible officer of the trustee has knowledge of such Default or Event of Default. The indenture provides that the trustee may withhold notice to
the holders of debt securities of any series of any Default or Event of Default (except in payment on any debt securities of that series) with respect to debt securities of that series if the trustee determines in good faith that withholding notice
is in the interest of the holders of those debt securities. (Section 7.5) </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Modification and Waiver </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We and the trustee may modify, amend or supplement the indenture or the debt securities of any series without the consent of any holder of any debt security:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to cure any ambiguity, defect or inconsistency; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with covenants in the indenture described above under the heading &#147;Consolidation, Merger and Sale
of Assets&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for uncertificated securities in addition to or in place of certificated securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add guarantees with respect to debt securities of any series or secure debt securities of any series;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to surrender any of our rights or powers under the indenture; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add covenants or events of default for the benefit of the holders of debt securities of any series;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with the applicable procedures of the applicable depositary; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to make any change that does not adversely affect the rights of any holder of debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for the issuance of and establish the form and terms and conditions of debt securities of any series
as permitted by the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to effect the appointment of a successor trustee with respect to the debt securities of any series and to add to
or change any of the provisions of the indenture to provide for or facilitate administration by more than one trustee; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with requirements of the SEC in order to effect or maintain the qualification of the indenture under
the Trust Indenture Act. (Section 9.1) </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may also modify and amend the indenture with the consent of the holders of at least a
majority in principal amount of the outstanding debt securities of each series affected by the modifications or amendments. We may not make any modification or amendment without the consent of the holders of each affected debt security then
outstanding if that amendment will: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the amount of debt securities whose holders must consent to an amendment, supplement or waiver;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the rate of or extend the time for payment of interest (including default interest) on any debt security;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the principal of or premium on or change the fixed maturity of any debt security or reduce the amount of,
or postpone the date fixed for, the payment of any sinking fund or analogous obligation with respect to any series of debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the principal amount of discount securities payable upon acceleration of maturity; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">waive a default in the payment of the principal of, premium or interest on any debt security (except a rescission
of acceleration of the debt securities of any series by the holders of at least a majority in aggregate principal amount of the then outstanding debt securities of that series and a waiver of the payment default that resulted from such
acceleration); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make the principal of or premium or interest on any debt security payable in currency other than that stated in
the debt security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any change to certain provisions of the indenture relating to, among other things, the right of holders of
debt securities to receive payment of the principal of, premium and interest on those debt securities and to institute suit for the enforcement of any such payment and to waivers or amendments; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">waive a redemption payment with respect to any debt security. (Section 9.3) </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except for certain specified provisions, the holders of at least a majority in principal amount of the outstanding debt securities of any series may on behalf
of the holders of all debt securities of that series waive our compliance with provisions of the indenture. (Section 9.2) The holders of a majority in principal amount of the outstanding debt securities of any series may on behalf of the holders of
all the debt securities of such series waive any past default under the indenture with respect to that series and its consequences, except a default in the payment of the principal of, premium or any interest on any debt security of that series;
provided, however, that the holders of a majority in principal amount of the outstanding debt securities of any series may rescind an acceleration and its consequences, including any related payment default that resulted from the acceleration.
(Section 6.13) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Defeasance of Debt Securities and Certain Covenants in Certain Circumstances </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Legal Defeasance</I>. The indenture provides that, unless otherwise provided by the terms of the applicable series of debt securities, we may be discharged
from any and all obligations in respect of the debt securities of any series (subject to certain exceptions). We will be so discharged upon the irrevocable deposit with the trustee, in trust, of money and/or U.S. government obligations or, in the
case of debt securities denominated in a single currency other than U.S. Dollars, government obligations of the government that issued or caused to be issued such currency, that, through the payment of interest and principal in accordance with their
terms, will provide money or U.S. government obligations in an amount sufficient in the opinion of a nationally recognized firm of independent public accountants or investment bank to pay and discharge each installment of principal, premium and
interest on and any mandatory sinking fund payments in respect of the debt securities of that series on the stated maturity of those payments in accordance with the terms of the indenture and those debt securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This discharge may occur only if, among other things, we have delivered to the trustee an opinion of counsel stating that we have received from, or there has
been published by, the United States Internal Revenue Service a ruling or, since the date of execution of the indenture, there has been a change in the applicable U.S. federal income tax law, in either case to the effect that, and based thereon such
opinion shall confirm that, the holders of the debt securities of that series will not recognize income, gain or loss for U.S. federal income tax purposes as a result of the deposit, defeasance and discharge and will be subject to U.S. federal
income tax on the same amounts and in the same manner and at the same times as would have been the case if the deposit, defeasance and discharge had not occurred. (Section 8.3) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Defeasance of Certain Covenants</I>. The indenture provides that, unless otherwise provided by the terms of the applicable series of debt securities, upon
compliance with certain conditions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may omit to comply with the covenant described under the heading &#147;Consolidation, Merger and Sale of
Assets&#148; and certain other covenants set forth in the indenture, as well as any additional covenants which may be set forth in the applicable prospectus supplement; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any omission to comply with those covenants will not constitute a Default or an Event of Default with respect to
the debt securities of that series (&#147;covenant defeasance&#148;). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The conditions include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">depositing with the trustee money and/or U.S. government obligations or, in the case of debt securities
denominated in a single currency other than U.S. Dollars, government obligations of the government that issued or caused to be issued such currency, that, through the payment of interest and principal in accordance with their terms, will provide
money in an amount sufficient in the opinion of a nationally recognized firm of independent public accountants or investment bank to pay and discharge each installment of principal of, premium and interest on and any mandatory sinking fund payments
in respect of the debt securities of that series on the stated maturity of those payments in accordance with the terms of the indenture and those debt securities; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delivering to the trustee an opinion of counsel to the effect that the holders of the debt securities of that
series will not recognize income, gain or loss for U.S. federal income tax purposes as a result of the deposit and related covenant defeasance and will be subject to U.S. federal income tax on the same amounts and in the same manner and at the same
times as would have been the case if the deposit and related covenant defeasance had not occurred. (Section 8.4) </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Personal
Liability of Directors, Officers, Employees or Securityholders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None of our past, present or future directors, officers, employees or securityholders,
as such, will have any liability for any of our obligations under the debt securities or the indenture or for any claim based on, or in respect or by reason of, such obligations or their creation. By accepting a debt security, each holder waives and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
releases all such liability. This waiver and release is part of the consideration for the issue of the debt securities. However, this waiver and release may not be effective to waive liabilities
under U.S. federal securities laws, and it is the view of the SEC that such a waiver is against public policy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The indenture and the debt securities, including any claim or controversy arising out of or relating to the indenture or the securities, will be governed by
the laws of the State of New York. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The indenture will provide that we, the trustee and the holders of the debt securities (by their acceptance of the
debt securities) irrevocably waive, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to the indenture, the debt securities or the transactions contemplated
thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The indenture will provide that any legal suit, action or proceeding arising out of or based upon the indenture or the transactions contemplated
thereby may be instituted in the federal courts of the United States of America located in the City of New York or the courts of the State of New York in each case located in the City of New&nbsp;York, and we, the trustee and the holder of the debt
securities (by their acceptance of the debt securities) irrevocably submit to the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> jurisdiction of such courts in any such suit, action or proceeding. The indenture will further provide that
service of any process, summons, notice or document by mail (to the extent allowed under any applicable statute or rule of court) to such party&#146;s address set forth in the indenture will be effective service of process for any suit, action or
other proceeding brought in any such court. The indenture will further provide that we, the trustee and the holders of the debt securities (by their acceptance of the debt securities) irrevocably and unconditionally waive any objection to the laying
of venue of any suit, action or other proceeding in the courts specified above and irrevocably and unconditionally waive and agree not to plead or claim any such suit, action or other proceeding has been brought in an inconvenient forum. (Section
10.10) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca446052_8"></A>DESCRIPTION OF WARRANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue warrants for the purchase of shares of our common stock or preferred stock or of debt securities. We may issue warrants independently or together
with other securities, and the warrants may be attached to or separate from any offered securities. Each series of warrants will be issued under a separate warrant agreement to be entered into between us and the investors or a warrant agent. The
following summary of material provisions of the warrants and warrant agreements are subject to, and qualified in their entirety by reference to, all the provisions of the warrant agreement and warrant certificate applicable to a particular series of
warrants. The terms of any warrants offered under a prospectus supplement may differ from the terms described below. We urge you to read the applicable prospectus supplement and any related free writing prospectus, as well as the complete warrant
agreements and warrant certificates that contain the terms of the warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The particular terms of any issue of warrants will be described in the
prospectus supplement relating to the issue. Those terms may include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares of common stock or preferred stock purchasable upon the exercise of warrants to purchase
such shares and the price at which such number of shares may be purchased upon such exercise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation, stated value and terms (including, without limitation, liquidation, dividend, conversion and
voting rights) of the series of preferred stock purchasable upon exercise of warrants to purchase preferred stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the principal amount of debt securities that may be purchased upon exercise of a debt warrant and the exercise
price for the warrants, which may be payable in cash, securities or other property; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date, if any, on and after which the warrants and the related debt securities, preferred stock or common
stock will be separately transferable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of any rights to redeem or call the warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date on which the right to exercise the warrants will commence and the date on which the right will expire;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">U.S. federal income tax consequences applicable to the warrants; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any additional terms of the warrants, including terms, procedures, and limitations relating to the exchange,
exercise and settlement of the warrants. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of equity warrants will not be entitled: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to vote, consent or receive dividends; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">receive notice as stockholders with respect to any meeting of stockholders for the election of our directors or
any other matter; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exercise any rights as stockholders of Annexon. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each warrant will entitle its holder to purchase the principal amount of debt securities or the number of shares of preferred stock or common stock at the
exercise price set forth in, or calculable as set forth in, the applicable prospectus supplement. Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants at any time up to the specified
time on the expiration date that we set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will become void. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A holder of warrant certificates may exchange them for new warrant certificates of different denominations,
present them for registration of transfer and exercise them at the corporate trust office of the warrant agent or any other office indicated in the applicable prospectus supplement. Until any warrants to purchase debt securities are exercised, the
holder of the warrants will not have any rights of holders of the debt securities that can be purchased upon exercise, including any rights to receive payments of principal, premium or interest on the underlying debt securities or to enforce
covenants in the applicable indenture. Until any warrants to purchase common stock or preferred stock are exercised, the holders of the warrants will not have any rights of holders of the underlying common stock or preferred stock, including any
rights to receive dividends or payments upon any liquidation, dissolution or winding up on the common stock or preferred stock, if any. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca446052_9"></A>DESCRIPTION OF UNITS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue units consisting of any combination of the other types of securities offered under this prospectus in one or more series. We may evidence each
series of units by unit certificates that we will issue under a separate agreement. We may enter into unit agreements with a unit agent. Each unit agent will be a bank or trust company that we select. We will indicate the name and address of the
unit agent in the applicable prospectus supplement relating to a particular series of units. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following description, together with the additional
information included in any applicable prospectus supplement, summarizes the general features of the units that we may offer under this prospectus. You should read any prospectus supplement and any free writing prospectus that we may authorize to be
provided to you related to the series of units being offered, as well as the complete unit agreements that contain the terms of the units. Specific unit agreements will contain additional important terms and provisions and we will file as an exhibit
to the registration statement of which this prospectus is a part, or will incorporate by reference from another report that we file with the SEC, the form of each unit agreement relating to units offered under this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we offer any units, certain terms of that series of units will be described in the applicable prospectus supplement, including, without limitation, the
following, as applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of the series of units; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identification and description of the separate constituent securities comprising the units;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price or prices at which the units will be issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date, if any, on and after which the constituent securities comprising the units will be separately
transferable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a discussion of certain U.S. federal income tax considerations applicable to the units; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other terms of the units and their constituent securities. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca446052_10"></A>GLOBAL SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Book-Entry, Delivery and Form </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless we indicate
differently in any applicable prospectus supplement or free writing prospectus, the securities initially will be issued in book-entry form and represented by one or more global notes or global securities, or, collectively, global securities. The
global securities will be deposited with, or on behalf of, The Depository Trust Company, New York, New York, as depositary, or DTC, and registered in the name of Cede&nbsp;&amp; Co., the nominee of DTC. Unless and until it is exchanged for
individual certificates evidencing securities under the limited circumstances described below, a global security may not be transferred except as a whole by the depositary to its nominee or by the nominee to the depositary, or by the depositary or
its nominee to a successor depositary or to a nominee of the successor depositary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DTC has advised us that it is: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a limited-purpose trust company organized under the New York Banking Law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a &#147;banking organization&#148; within the meaning of the New York Banking Law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a member of the Federal Reserve System; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a &#147;clearing corporation&#148; within the meaning of the New York Uniform Commercial Code; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a &#147;clearing agency&#148; registered pursuant to the provisions of Section&nbsp;17A of the Exchange Act.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DTC holds securities that its participants deposit with DTC. DTC also facilitates the settlement among its participants of securities
transactions, such as transfers and pledges, in deposited securities through electronic computerized book-entry changes in participants&#146; accounts, thereby eliminating the need for physical movement of securities certificates. &#147;Direct
participants&#148; in DTC include securities brokers and dealers, including underwriters, banks, trust companies, clearing corporations and other organizations. DTC is a wholly-owned subsidiary of The Depository Trust&nbsp;&amp; Clearing
Corporation, or DTCC. DTCC is the holding company for DTC, National Securities Clearing Corporation and Fixed Income Clearing Corporation, all of which are registered clearing agencies. DTCC is owned by the users of its regulated subsidiaries.
Access to the DTC system is also available to others, which we sometimes refer to as indirect participants, that clear through or maintain a custodial relationship with a direct participant, either directly or indirectly. The rules applicable to DTC
and its participants are on file with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Purchases of securities under the DTC system must be made by or through direct participants, which will
receive a credit for the securities on DTC&#146;s records. The ownership interest of the actual purchaser of a security, which we sometimes refer to as a beneficial owner, is in turn recorded on the direct and indirect participants&#146; records.
Beneficial owners of securities will not receive written confirmation from DTC of their purchases. However, beneficial owners are expected to receive written confirmations providing details of their transactions, as well as periodic statements of
their holdings, from the direct or indirect participants through which they purchased securities. Transfers of ownership interests in global securities are to be accomplished by entries made on the books of participants acting on behalf of
beneficial owners. Beneficial owners will not receive certificates representing their ownership interests in the global securities, except under the limited circumstances described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To facilitate subsequent transfers, all global securities deposited by direct participants with DTC will be registered in the name of DTC&#146;s partnership
nominee, Cede&nbsp;&amp; Co., or such other name as may be requested by an authorized representative of DTC. The deposit of securities with DTC and their registration in the name of Cede&nbsp;&amp; Co. or such other nominee will not change the
beneficial ownership of the securities. DTC has no knowledge of the actual beneficial owners of the securities. DTC&#146;s records reflect only the identity of the direct participants to whose accounts the securities are credited, which may or may
not be the beneficial owners. The participants are responsible for keeping account of their holdings on behalf of their customers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">So long as the securities are in book-entry form, you will receive payments and may transfer securities only
through the facilities of the depositary and its direct and indirect participants. We will maintain an office or agency in the location specified in the prospectus supplement for the applicable securities, where notices and demands in respect of the
securities and the indenture may be delivered to us and where certificated securities may be surrendered for payment, registration of transfer or exchange. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Conveyance of notices and other communications by DTC to direct participants, by direct participants to indirect participants and by direct participants and
indirect participants to beneficial owners will be governed by arrangements among them, subject to any legal requirements in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Redemption notices will be sent to DTC. If less than all of the securities of a particular series are being redeemed, DTC&#146;s practice is to determine by
lot the amount of the interest of each direct participant in the securities of such series to be redeemed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither DTC nor Cede&nbsp;&amp; Co. (or such
other DTC nominee) will consent or vote with respect to the securities. Under its usual procedures, DTC will mail an omnibus proxy to us as soon as possible after the record date. The omnibus proxy assigns the consenting or voting rights of
Cede&nbsp;&amp; Co. to those direct participants to whose accounts the securities of such series are credited on the record date, identified in a listing attached to the omnibus proxy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">So long as securities are in book-entry form, we will make payments on those securities to the depositary or its nominee, as the registered owner of such
securities, by wire transfer of immediately available funds. If securities are issued in definitive certificated form under the limited circumstances described below and unless if otherwise provided in the description of the applicable securities
herein or in the applicable prospectus supplement, we will have the option of making payments by check mailed to the addresses of the persons entitled to payment or by wire transfer to bank accounts in the United States designated in writing to the
applicable trustee or other designated party at least 15 days before the applicable payment date by the persons entitled to payment, unless a shorter period is satisfactory to the applicable trustee or other designated party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Redemption proceeds, distributions and dividend payments on the securities will be made to Cede&nbsp;&amp; Co., or such other nominee as may be requested by
an authorized representative of DTC. DTC&#146;s practice is to credit direct participants&#146; accounts upon DTC&#146;s receipt of funds and corresponding detail information from us on the payment date in accordance with their respective holdings
shown on DTC records. Payments by participants to beneficial owners will be governed by standing instructions and customary practices, as is the case with securities held for the account of customers in bearer form or registered in &#147;street
name.&#148; Those payments will be the responsibility of participants and not of DTC or us, subject to any statutory or regulatory requirements in effect from time to time. Payment of redemption proceeds, distributions and dividend payments to
Cede&nbsp;&amp; Co., or such other nominee as may be requested by an authorized representative of DTC, is our responsibility, disbursement of payments to direct participants is the responsibility of DTC, and disbursement of payments to the
beneficial owners is the responsibility of direct and indirect participants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except under the limited circumstances described below, purchasers of
securities will not be entitled to have securities registered in their names and will not receive physical delivery of securities. Accordingly, each beneficial owner must rely on the procedures of DTC and its participants to exercise any rights
under the securities and the indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The laws of some jurisdictions may require that some purchasers of securities take physical delivery of
securities in definitive form. Those laws may impair the ability to transfer or pledge beneficial interests in securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DTC may discontinue providing
its services as securities depositary with respect to the securities at any time by giving reasonable notice to us. Under such circumstances, in the event that a successor depositary is not obtained, securities certificates are required to be
printed and delivered. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As noted above, beneficial owners of a particular series of securities generally will not receive
certificates representing their ownership interests in those securities. However, if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">DTC notifies us that it is unwilling or unable to continue as a depositary for the global security or securities
representing such series of securities or if DTC ceases to be a clearing agency registered under the Exchange Act at a time when it is required to be registered and a successor depositary is not appointed within 90 days of the notification to us or
of our becoming aware of DTC&#146;s ceasing to be so registered, as the case may be; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we determine, in our sole discretion, not to have such securities represented by one or more global securities;
or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an Event of Default has occurred and is continuing with respect to such series of securities,
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">we will prepare and deliver certificates for such securities in exchange for beneficial interests in the global securities. Any
beneficial interest in a global security that is exchangeable under the circumstances described in the preceding sentence will be exchangeable for securities in definitive certificated form registered in the names that the depositary directs. It is
expected that these directions will be based upon directions received by the depositary from its participants with respect to ownership of beneficial interests in the global securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Euroclear and Clearstream </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If so provided in the
applicable prospectus supplement, you may hold interests in a global security through Clearstream Banking S.A., which we refer to as &#147;Clearstream,&#148; or Euroclear Bank S.A./N.V., as operator of the Euroclear System, which we refer to as
&#147;Euroclear,&#148; either directly if you are a participant in Clearstream or Euroclear or indirectly through organizations which are participants in Clearstream or Euroclear. Clearstream and Euroclear will hold interests on behalf of their
respective participants through customers&#146; securities accounts in the names of Clearstream and Euroclear, respectively, on the books of their respective U.S. depositaries, which in turn will hold such interests in customers&#146; securities
accounts in such depositaries&#146; names on DTC&#146;s books. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clearstream and Euroclear are securities clearance systems in Europe. Clearstream and
Euroclear hold securities for their respective participating organizations and facilitate the clearance and settlement of securities transactions between those participants through electronic book-entry changes in their accounts, thereby eliminating
the need for physical movement of certificates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payments, deliveries, transfers, exchanges, notices and other matters relating to beneficial interests in
global securities owned through Euroclear or Clearstream must comply with the rules and procedures of those systems. Transactions between participants in Euroclear or Clearstream, on one hand, and other participants in DTC, on the other hand, are
also subject to DTC&#146;s rules and procedures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors will be able to make and receive through Euroclear and Clearstream payments, deliveries,
transfers and other transactions involving any beneficial interests in global securities held through those systems only on days when those systems are open for business. Those systems may not be open for business on days when banks, brokers and
other institutions are open for business in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cross-market transfers between participants in DTC, on the one hand, and participants in
Euroclear or Clearstream, on the other hand, will be effected through DTC in accordance with the DTC&#146;s rules on behalf of Euroclear or Clearstream, as the case may be, by their respective U.S. depositaries; however, such cross-market
transactions will require delivery of instructions to Euroclear or Clearstream, as the case may be, by the counterparty in such system in accordance with the rules and procedures and within the established deadlines (European time) of such system.
Euroclear or Clearstream, as the case may be, will, if the transaction meets its settlement requirements, deliver instructions to its U.S. depositary to take action to effect final settlement on its behalf by delivering or receiving interests in the
global securities through DTC, and making or receiving payment in accordance with normal procedures for <FONT STYLE="white-space:nowrap">same-day</FONT> fund settlement. Participants in Euroclear or Clearstream may not deliver instructions directly
to their respective U.S. depositaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Due to time zone differences, the securities accounts of a participant in Euroclear or Clearstream
purchasing an interest in a global security from a direct participant in DTC will be credited, and any such crediting will be reported to the relevant participant in Euroclear or Clearstream, during the securities settlement processing day (which
must be a business day for Euroclear or Clearstream) immediately following the settlement date of DTC. Cash received in Euroclear or Clearstream as a result of sales of interests in a global security by or through a participant in Euroclear or
Clearstream to a direct participant in DTC will be received with value on the settlement date of DTC but will be available in the relevant Euroclear or Clearstream cash account only as of the business day for Euroclear or Clearstream following
DTC&#146;s settlement date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
information in this section of this prospectus concerning DTC, Clearstream, Euroclear and their respective book-entry systems has been obtained from sources that we believe to be reliable, but we do not take responsibility for this information. This
information has been provided solely as a matter of convenience. The rules and procedures of DTC, Clearstream and Euroclear are solely within the control of those organizations and could change at any time. Neither we nor the trustee nor any agent
of ours or of the trustee has any control over those entities and none of us takes any responsibility for their activities. You are urged to contact DTC, Clearstream and Euroclear or their respective participants directly to discuss those matters.
In addition, although we expect that DTC, Clearstream and Euroclear will perform the foregoing procedures, none of them is under any obligation to perform or continue to perform such procedures and such procedures may be discontinued at any time.
Neither we nor any agent of ours will have any responsibility for the performance or nonperformance by DTC, Clearstream and Euroclear or their respective participants of these or any other rules or procedures governing their respective operations.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca446052_11"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may sell the securities from time to time pursuant to underwritten public offerings, negotiated transactions, block trades or a combination of these
methods or through underwriters or dealers, through agents and/or directly to one or more purchasers. The securities may be distributed from time to time in one or more transactions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a fixed price or prices, which may be changed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at market prices prevailing at the time of sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at prices related to such prevailing market prices; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at negotiated prices. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each time that we sell securities covered by this prospectus, we will provide a prospectus supplement or supplements that will describe the method of
distribution and set forth the terms and conditions of the offering of such securities, including the offering price of the securities and the proceeds to us, if applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Offers to purchase the securities being offered by this prospectus may be solicited directly. Agents may also be designated to solicit offers to purchase the
securities from time to time. Any agent involved in the offer or sale of our securities will be identified in a prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a dealer is
utilized in the sale of the securities being offered by this prospectus, the securities will be sold to the dealer, as principal. The dealer may then resell the securities to the public at varying prices to be determined by the dealer at the time of
resale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an underwriter is utilized in the sale of the securities being offered by this prospectus, an underwriting agreement will be executed with the
underwriter at the time of sale and the name of any underwriter will be provided in the prospectus supplement that the underwriter will use to make resales of the securities to the public. In connection with the sale of the securities, we or the
purchasers of securities for whom the underwriter may act as agent, may compensate the underwriter in the form of underwriting discounts or commissions. The underwriter may sell the securities to or through dealers, and those dealers may receive
compensation in the form of discounts, concessions or commissions from the underwriters and/or commissions from the purchasers for which they may act as agent. Unless otherwise indicated in a prospectus supplement, an agent will be acting on a best
efforts basis and a dealer will purchase securities as a principal, and may then resell the securities at varying prices to be determined by the dealer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any compensation paid to underwriters, dealers or agents in connection with the offering of the securities, and any discounts, concessions or commissions
allowed by underwriters to participating dealers will be provided in the applicable prospectus supplement. Underwriters, dealers and agents participating in the distribution of the securities may be deemed to be underwriters within the meaning of
the Securities Act of 1933, as amended, and any discounts and commissions received by them and any profit realized by them on resale of the securities may be deemed to be underwriting discounts and commissions. We may enter into agreements to
indemnify underwriters, dealers and agents against civil liabilities, including liabilities under the Securities Act, or to contribute to payments they may be required to make in respect thereof and to reimburse those persons for certain expenses.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any common stock will be listed on the Nasdaq Global Select Market, but any other securities may or may not be listed on a national securities exchange.
To facilitate the offering of securities, certain persons participating in the offering may engage in transactions that stabilize, maintain or otherwise affect the price of the securities. This may include over-allotments or short sales of the
securities, which involve the sale by persons participating in the offering of more securities than were sold to them. In these circumstances, these persons would cover such over-allotments or short positions by making purchases in the open market
or by exercising their over-allotment option, if any. In addition, these persons may stabilize or maintain the price of the securities by bidding for or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
purchasing securities in the open market or by imposing penalty bids, whereby selling concessions allowed to dealers participating in the offering may be reclaimed if securities sold by them are
repurchased in connection with stabilization transactions. The effect of these transactions may be to stabilize or maintain the market price of the securities at a level above that which might otherwise prevail in the open market. These transactions
may be discontinued at any time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may engage in at the market offerings into an existing trading market in accordance with Rule 415(a)(4) under the
Securities Act. In addition, we may enter into derivative transactions with third parties, or sell securities not covered by this prospectus to third parties in privately negotiated transactions. If the applicable prospectus supplement so indicates,
in connection with those derivatives, the third parties may sell securities covered by this prospectus and the applicable prospectus supplement, including in short sale transactions. If so, the third party may use securities pledged by us or
borrowed from us or others to settle those sales or to close out any related open borrowings of stock, and may use securities received from us in settlement of those derivatives to close out any related open borrowings of stock. The third party in
such sale transactions will be an underwriter and, if not identified in this prospectus, will be named in the applicable prospectus supplement (or a post-effective amendment). In addition, we may otherwise loan or pledge securities to a financial
institution or other third party that in turn may sell the securities short using this prospectus and an applicable prospectus supplement. Such financial institution or other third party may transfer its economic short position to investors in our
securities or in connection with a concurrent offering of other securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The specific terms of any <FONT STYLE="white-space:nowrap">lock-up</FONT>
provisions in respect of any given offering will be described in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters, dealers and agents may engage in
transactions with us, or perform services for us, in the ordinary course of business for which they receive compensation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca446052_12"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Latham&nbsp;&amp; Watkins LLP will pass upon certain legal matters relating to the issuance and sale of the securities offered hereby on behalf of Annexon,
Inc. Additional legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toca446052_13"></A>EXPERTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
consolidated financial statements of Annexon, Inc. as of December&nbsp;31, 2021 and 2020, and for each of the years in the <FONT STYLE="white-space:nowrap">two-year</FONT> period ended December&nbsp;31, 2021, and management&#146;s assessment of the
effectiveness of internal control over financial reporting as of December&nbsp;31, 2021 have been incorporated by reference herein in reliance upon the report of KPMG LLP, independent registered public accounting firm, incorporated by reference
herein, and upon the authority of said firm as experts in accounting and auditing. The audit report covering the December&nbsp;31, 2021 financial statements refers to a change to the accounting for leases. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g446052g01g01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:30pt; margin-bottom:0pt; font-size:20pt; font-family:ARIAL" ALIGN="center"><B>25,035,000 Shares of Common stock </B></P>
<P STYLE="margin-top:30pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Pre-funded Warrants to Purchase 18,379,861 Shares of Common Stock </B></P>
<P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</P></center> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL"><B>Jefferies </B></P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="right"><B>TD Cowen </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">December&nbsp;20, 2023 </P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g446052g01a02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g446052g01a02.jpg
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M<8>1&1HD,SDZ0E)76):7M-8F8G.2E+'4U?_$ !X!   & P$!
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M]$NS#.>W+_3[@H?.(U$51"5CJZ;FYC%(02K*>A:*4 M$Q /HLA])&UQ8X_\
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M$\:_+)$HE '0=BY[VU03W0;A3Y_9;!Q=M5-FIL;1;:W2T:=6M%;4.]DN$Q
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M1D$%%!!!Z$$=XU,WEVN\7 .LDC=HY(]V;8>.1&*.CI4SLCHZD,K*P#*RD%2
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M@2LD*=;L"P$]55JI9)$8UP<"'64BK*"ZZI&4 0"1EQ%LO;TT5Z@3ZK2!8*O
MZM3.WU*0^LPRMRD]Y27)/+&,=&O(#XPFS;CN7"&]51%MW.TUYVJ97/)3;AI*
M8-<;?&6.$2[6VF%3&N51:NV<D:M/<&)7WV-[QKALBSDQR]6H@+5$NH.6J]SI
M"TJ>%:6ROR:1%D&RDD1C)^0=14XTBIMB\"/<G*K'G9F*#9\Z T;[?O<]@N"U
ML2=LAC>&>G+]FLT;C(!?E?E*2*DBMRL<J5QACKH3QUX-6?CCL6?9]RK/>FLB
MKZ2ZV6^)2+6RVFX4S&.204QGIO.(:NAFJZ*>$U$0*U"S ]K!%BNF2<@VW,&1
M+EDNZ/U9BY9 L\M9YUV!3CYB5FWRKM5%HAW'%!H@98K2.9)#X3-FBW9MRE11
M3("955,U;53U<[%YZF9YI&];R,6( \%!.%4=%4!1T U(^V=NVC9VW+-MBRP)
M1V;;UKI+70Q94=G2T,"Q+),^%#S2!#-4SMZ4TSR32$N[$O<],[:(CL[VN5*E
MR[)%')UR[+]EAT4"'7);)IJW!"N>.7N$S6G1";&OD(DJ=FK)-9:5:@099;NL
M)M6RBR6B&!U JY\5-8>F1-(HQ%D9]&! L70E2ZNX^&=<&?*:XP2<9.*=WO=)
M/(^U[-S6#:4)YE0VBBEDY[EV9QB:\UC3W%F9%F2FEI*27/FB8U3UK91>.Z=>
M96Z)S$"9G<51:XE$0$4 RA4Y,Q!$/7M.>-3*8/@8HB4>0$0$GOMRNV:X X[2
M2C0^SSN%\?\ R:=GD2TL=3Y1NRY) &-%0[KJHP>H$G[%KO3 X]:BI8CU$ CJ
M!I&( $1   1$1X  ]1$1^  'X1'5?]=V"0 23@#J2>X#UG734IL&E6*A5:T@
MF"2%>K<'!HI%  *FE$QC5@FF4 ]  A&X%  ]  .-6K@C$,$,0&!%%'& .X!$
M"@#V8U\Q-YKGN=WNMRD8L]QN5=7.Q.2SU=5+4,Q/B29"2?$G62:VZ3=+7^T9
MP+9>C;6[.*9?.1ELR? D5   XMIR'I\@HF(\<F*56O)&* CP43'$H?/,.HMX
MG1@T]HE^V2:KC'LD2!C_ $Q#V?EUTM]S@KY8[]Q4M88]C56C:]>R9Z=K05MX
MIU8#P)6XN"0.H SW#00.F7,#!;^-K#T#BF*^58F'[@'CD+$T?U\Q.?Q*%DQ3
M$/\ 2 _;Z\\:8.U'[/<5H;.,UB)_VJM%C\O/C5Y/*>HQ7< .*L!7F";4JJS&
M,];=/3W -_\ I-,&SX8STQG30W73^@%9_K+QI^N%]2UQ ^+DWWU2?K#KEMY"
M/\(&U_BSN;Z''I1#:;]*?;1^<!AK]XM<U"]F^O%J_"5#]*BUU^XN?8IXG?XO
M=Z?V;N6BQ=>/:R.+=PD'N'K4:*--SVR,E8SMT>UK'91K#1LUE/%\,H)-QM5?
M+%S2 &X6D99E:GAN\Q%#:>/$.T>:7*.YQ)B"XKB7 Z)5Q !\XZ#MH^209ZNZ
MS-X:J7Y!'%4;IX>5_#JYU(>\[ G#VU9'S+4[6NDTLM-R\Q+R"U7$U5%(1Z%-
M25%J@ 4%0;->S^;L2@%ZV?6V2 #&,^R=B/S2WW7S4$L@51GXAOB %96^.8MR
M\B'RRD%?0!'2KPXO']\629_XU719/L%3"N3\BSHH'^'8ZC#W0;A*<V'C%:*;
M(Q!M?=_9)W$%WV_=IN4=QS/9ZF>0]XLU.O>-;2]HJ^\IMU^M*S_LF&CG$WZW
MVS[\E_4'36]SE^._$;\5;7_6^@3],3Z<>$/ZROW0W_4>[3^,%!_E7T*IU?#R
MHOL%;Y_S9_MAM_3=W57SL& =CF:)YF\\G9;W$$Q'41*IX2YY?(95H>269J@(
M'3>150"SSS51/E0BT24Q.T0\0DT;PN/O;M^ND5N66H044'7!+U.4<J>\,D';
M2*1U!0>W7('R4=A_M@\=-E6^:'MK98JP[OO *\T:T>W"E;3),N"&AJ[O[UV^
M56PK)5D-D'E9!O5===_-'*H77GW)XWHU,QY6,+[>VM;H=5KU-K[<\3D85$(6
MLQ+2%BTE#)Y$23,H1DR0*H8B9"F.!C 0H#P#_IN(=UI:>"FBH;8(J>&*",&.
MJR(XD6- <50&>51GH.NJ*7_R!N&NY+[>MQ7/>W$*6Y7ZZW&\W"1:K;@5ZVYU
M<U;5,H;;S,%:>=RH+,0" 2>_5+=\'4&R5OP4QTZR=0,:5.1QJ2RMXB3H3.SL
MW<@RM!H51VQEQG[-/IN&[->#0<1P($;';*NGXB8Y7)@*A7_<E7N'S8U=/20M
M2]J$>F652RS=F65^UEER 8P5QRX);.<])LX&^3SMK@(NXXML;AW-=Z;<QMDE
M72W^:V2PT\]K%:L,](+?;:!HY9HZZ2.H+F02+%!T4Q GTNEGGC^#[O?PM9GK
MWR=9N4T.*;B8ZGA-A@LABE!M'+U01 J;*%LYZ[8G)S<E*G#")@X =9[1N'O;
M?Z"5FQ%/)YG/UP.SJL1J6/@L<QBE/R1Z+>55L+]L+@;O6V00=O=++1#=EF 7
MGE%=MWFKIHX% ):>MM8N-NC4=2U9@==/W:L7KY_]<_3J<?3ZW3?6C(_J^-U7
M#=GQCN_WVWZ":^@_R7_X/_"O\5J?Z34Z8/\ 9XOHL9F_. ?_ +NJ!J2.&GUI
MK_PB?HU/KGE[HI]E;9G^+VF_M)N'0T.NIM0##NXN.SY5HT&]%W").GTT#9'M
M:Q658-)NG9TU 3+X:'RLCU8^T(G6/XTC,J6Q8A?#:&$&MQ!L_F-S6XPIBGN0
M9I,#HE9&!VP..[ME*S GJ\AF(Z+JS7D(<6OV8\.:GA_=:GM+[P\:*"A[5\RU
M>U*YY&MC+S=7]Z*E:BU.J I342VA&(:89M9[/WNO,![YL_MDER4Q7V3\1@Z6
M^Y,7P$<@55GXAO@<HL+=',&Y0 HDN4@IR)Q$%CAQ>/[YLDS_ ,:KHLGV"IA&
M3_,F10/\.Q[]1/[H/PF&+#QBM--US!M;=W9)W])'V_=IN7U8GM%3/)WYLU.I
MZ :76S?]^G+WUH7_ /:N6U&5?_?U;]]U/ZY]=&]C?$G9_P"*VW_ZII-.>]$0
M0'IY8OX$!XMV4P'^8?E].#P/XAX$!_H$!_#J<]A?%JD^[5GTF37%GRXOX1.Z
M?P1M7^S]#H8WM&O\M-JGY+Y8_6U$TU.)W[_9_N5;^G3:L_[F_P#67BO^%-H_
M1+_JG?0G^GU _5;DG_H&&D/A]\8XOO2J_074R>7C]@"O_&K;7Z^HT9KKK[5/
MLO[<8W/=8C1<7C;VY</ID6R7<ZD\63ZS9"S)J F7O7^2\FG%V9(ZIA1CH=.U
M+$*!G1Q%\\0;/Y[:UN,29J+:2TF!U:CD($N?$]BP24=<*@F/CJEOD(<5_P!A
MW$FHV#=*GL[%Q#CCIZ/M7Q%2[JMZ2R6MUYCRI[Z4S55K<(.>IK'M2,<1 !>_
MI:;KAVG;M:589R2%CC3(AD\:9.\944V+2!L3QL6+LSGN$4D@J-A2C)IR[\-1
MP2#2G&3?M&04[HVVC>/>:\P2R-RTE3^Y:O)PJQR,.24^ [&4)(Q[^S$BCX6N
MAOE5<)AQ:X17NWT--V^YMN!MS[7Y$YIYJ^W0RFKMD>!S/[[VYJJBBBYEC:N:
MAFDSYNN+.]?<0'?'"" @(#@2@" @/(" V6_" @(>@@(? =*W$;Z_Q_@ZF_6U
M.HP]S_Z<"ZW/_/[<']66#6[O9U_OY;AOJHKW[7HZ/\,OKA<_O.+]>-,?W1KX
MB\.OQLN/]3OHMG6X_P G?E;\J<5_O$KVGEOWXLUGW:C^DQZJ-Y#_ /"*VG^"
MMU_V<N.DB*U&(S5C@(9PHHDWEIJ*C%U4>WQDT7[Y!JJHEWE,3Q"$5,8G>4Q>
MX [BB'(# D2"26-"2 \B(2.\!F )'R]==P[I5/0VVXUL2H\E'0U=5&DF>1GI
MZ>25%?E*MR,R -RD'!."#UTW"/L\6UGD>W,^?P#\ "^QT(_I$*$4!_L#4S?M
M:6C_ (_<?]*F_P#+ZY$#W13BKX[+X?9^2GW&/Z/V0'\^OY_>\.UK_;/G[_YN
M._\ L/0_:TM/_'[C\]-_Y?0_NBG%7_F7P^_U?<?_ /8-$JV2[&\;;%J3;Z/C
M:U7BUL+I9T;5)O+PX@5W;=\A%-HA-NP"!@H-%-H+=JFH<KA-RL*QCF*L5,2I
ME=5AL%+M^GFIZ6:HF6>43.U08RP8($PO9QQ@+A0>H)SXXZ:K1QOXY[EX[WRS
MWW<UJL5IJ++:WM-+#8HJ^.&2G>KEK&DJ/?"OKW:;M9F4&-HD$84%"P+&ZFEW
M4)Z7%Z^.\(*O2JWL_I4H!9V_)L+MEM1HJ'B,*5'/Q5J=77,F(BFM99]@:=?H
M"9)RC&5^-*J15A8?G1AQ%O?8P162!_JE2%J*T@]5@5LPPG'C+(ID8="$B3.5
MEUTB\@+@Y[ZWRY<8;W2DT&WFGLFT5F0\M1?*B#DNUTC# <R6N@G%# X#QO57
M&H*LM1;^@%=ANS&U;XLXH8JA)92JUR+@)2TWF\>[!E4:Q"LDP;1_8R,Y8I/9
M&:GG4;$LF0O4%/!7?20 JWBW10CO;UBFO]P%'&YAB2-YJBHY.<1(HPOH\R\S
M/(415Y@<%F[E.K\\?.-5JX&;%?==;2)=KE5W"EM5BL9J?-7N=;,QEJ"TXBG>
M&GHJ"*IJYINQ=>=(*8E9*J(FM>4L;6[#&2KMBV\,3Q5QQ[9Y6L3C8HG\,LA$
M.U&XNV2QB)F<1[TA$W\6^(4$WL>X:O$!%)9,PI=92S4-544=0O)-33/#(/#F
M1B.93TRK !D;N92&'0ZDS:NY;/O7;-DW58YUJ[-N*UTMTH92%YC3UD*R=C.@
M+".H@9FIZJ!B6@J(Y89 '1@'FNEON^3W>[6:O/3TB5WE7' -L>Y5244*9Z]F
MXIFE[HMZI!$%#I72%!M++N022;#8"6&/:@)(PPA/^TKT+U:(I)'YJREQ35@)
M])I$7T)B._$\>')P!V@E49Y-<*?*FX/-P>XJ76WT%,8=J;C,FX=ILJD00T-7
M,WG=H0@<H:RUIEHTB+-*+>;=42GFJ1K#^M%$*2O3GSHLD43GAI#%DOVE !'P
MT\L4IBN;C\22#]54XAZ@0AA^ "&M.^D+[8N!'VC4;_D\\@4_,&S[!I8\BNL6
MD\H_8:,0%K8-U4>2<#F;:5[GC'M:2!$4>+,!XZ1:06,W717( "=!5-8@&#DH
MF3.!R@8/PAR4.0_"&J_ X(/J(/S:[N2()(Y(VR%D1D.._#J5./EP==.&'E&L
MY$14TQ."C*8C6,HS4*(&*=K(-4G;<X&#T$#)+$, AZ" \AJUJ.LB)(IRKJKJ
M?6K ,#\QU\P=92RT-9544X*ST=3/2S*1@K+3RM%("#U!#H1CPUZ6LM%M+;>T
M92B:./-KL*)P!:0N>2Y0B?(=QDXB#J;14X!\1 AIQ(HC\ $X /Q#47<3G IK
M0GBT]6X'R)'"#^L'SZZ4^YPTK/N/BE6A<I3V3;-*S> :LKKM,JY_E"A<_+RG
MU:!5TW6R;O?AM4250(X*3,E4<@FH7O*51DY.\17 /7@[99 CE,W^@HD0_IV\
MZC[:X#;ALX(!_=T)P>O53S ^U2 P]1 /35[_ "E9&BX"<5V1VC)V;=8RRG!*
MS1K"Z$_Q94D:-A]LKE?'32O73^@%9_K+QI^N%]2YQ ^+DWWU2?K#KE?Y"/\
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M,J(JCJ69B H'4D@#730(<BA"*)G*HFH4IR'(8#$.0P 8IR&*(E,4Q1 2F 1
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M=8V6N8%K,Q"R\S%NDGL6ID&V231W:XZ/>-SJ-7B<-'P58C'SA!0P)33>5C5
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ML<C\M1!5U\3BNNL(&74VBVBIJH9^4QQW V^*4CSA0SZ@            !P
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M,=P10J2:INAJ%IIC(RLP,;( N,Y+*<]2.F%.BE=3M4PB-&12)%;+D@8"L,=
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M#&XR$J2O5.BTIM*Q,?$PQ$8*94(T:2,8R9(QZ8J%=O'AEA5)IH+;'&J19+Y
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M0TJF[2"R,6T+,1HNF46[:^[GZ@(N/(KNX\KE5N$@T!9<K*I*8H7@,H8'#8&
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MJB5[/R3"?A5&S^65?NIV5<&]Y)N)%01\N!@*L5(H)%%2[&-6$@8!>F$YF#=
M5/=C '3II8KXF--&HE8&,J2W7F?E7EZD,,9R2>_KI2-X3)"3@6I\NW=8IC'*
M)C3,]P/:'Q$@SY@'GGX"/]NEOGC_ ,"GS+_X=(&9/\*_^DW_ (M':Z0_3*QA
MDI^MN8R[:'>1$()Q+Q,7C9[ E9PKJ8FXITR<SUEF%)N1>3I6[.0=*,8Y)G%B
ME+>6DW#]T#<&ATZOKI%'81J(P0"7!RV 0<*  %Z]YZY&1TSI3M]$CDS2,7QT
2"$="6!!+'))Z'H.G7KD]VO_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g446052g01g01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g446052g01g01.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1MB4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &T:^:8(X0DE-! 0      #\< 5H  QLE1QP"   "   < E  "')R-C$S
M,C<W' (% !Y-:6-R;W-O9G0@5V]R9" M(%!R;R!3=7!P+F1O8W@ .$))300E
M       0VP#[;K()A_XZ5:M6]W$;BCA"24T$.@      Y0   !     !
M   +<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0
M  !);G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I
M;G1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    ,
M %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !
M $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7
M $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B
M;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L
M  !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0
M %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M          !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
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M8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M    "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#
MO_XU  (  3A"24T$)@      #@             _@   .$))300-       $
M    6CA"24T$&0      !    !XX0DE- _,       D           $ .$))
M32<0       *  $          3A"24T#]0      2  O9F8  0!L9F8 !@
M     0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U
M 0 M    !@       3A"24T#^       <   ________________________
M_____P/H     /____________________________\#Z     #_________
M____________________ ^@     _____________________________P/H
M   X0DE-! @      !     !   "0    D      .$))300>       $
M #A"24T$&@     #20    8              10   -V    "@!0 '( ;P @
M %, =0!P '  +0 Q     0                         !
M  -V   !%                      !                         !
M   !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL
M;VYG   !%     !29VAT;&]N9P   W8    &<VQI8V5S5FQ,<P    %/8FIC
M     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O
M=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M#6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !)
M;6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   10     4F=H
M=&QO;F<   -V     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M    37-G951%6%0    !       &86QT5&%G5$585     $       YC96QL
M5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z
M06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E
M<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +
M8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4
M   )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M#&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M.$))300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
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M!Q-5?^%:[U?9_-+)_P"=7UQ_\HG?YEO]RZ;H^5F9G0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                _^$[KVAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
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M(S%!>!<F,CEA=K4D-U&TMQHG5W%RD9*QUO_$ !X!  $$ P$! 0
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M8QGSD<AH*%PA7^&?E]68$QC_ -)$_P"/G/W]9UWIO)>[L_\ &ML7^Y O?_\
MF-:R?PG>%68$)1P4Q(Z&#?\ <B5^D>?=IP3_ !@P^C6B;@EN+DMR?X62U\V-
M)1](W?8'VQ8*H3B*6.':03B-%B/JLQ(5:4"Y;O!-IA)7+P9FV0OF:?:2/'G"
M\RCMRNNUWL#U-4ZT]PE:JC@E]G"",H.2&1X7!5N5\E@5PR],#5=O'C9O#/A=
MQKH[#MVDJ;YLBW4^V[A>;>U[>LFKHZIO:KK14]UI7BE@>6A9(H627G@F;G+=
MU"0M(=X3E_K_ )6UO7'+:V0"]?PNPG^O-LQ>*+5X%U72X=NZVYF_F4/&LGR
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MN7.S&2IK7NDC?(),#_:*O]W?&+_.FQO]#K/6OXH?M2T_R]5_F0:??W.K\?\
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MG\JU'V6BTPON@7SU6'\VUB_6'=FE'=^[ZXXO\"Z#^8+QTR.)/[HX_P FT_\
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MW9O*\U;DEHVM2&Q3Q5&:TB]46#0(]H:-H*4EY2'L5?B\F2\L:':)US'2$1$
M<2S5;%F[;M'@'+M;'2;_ -L7"XU,-UMT+57)3+3U-/& 9E$;R.DL:9YI0PD*
M,D8,B\JD*P+%):\%7B#V3L>PW7AKOFZ4^W%JK[+?+#?:]FCM4TE?24=)66VX
M5?)Y%L:%J".JIZRLDBHY5GFBDF@EBA6I4[JCD!W9-#4F)U7K9CR)K-.K&70(
M:MNM&N9O$,AV\.].R:'LE E9(#7XMP<@F6'7P[?)%(;B$CPC#+H[IO.VTT='
M2K=(8(,B.)K<S^6"2Q53+2NX7))"YP,^Z -=:;KX?>$_?M[J]U[FEX<72\W,
M0O67.+?45$:TQ0QPQS31VS<='322^3'&C3F+S90H,CNPSJ5VO,KO:/5H0S%R
M-<J)GPC .-+ N%?^64:JRG/[_P#CTM6_;_;Y(NI^JTK_ $?M/O\ 1Z::<O!C
MP30*6F_N;1!?E%^)DZX^L'=^>W7MVZ]M/SXF\@>3=<X!VS<O)^B[0L>]*:ZO
MRV--EM;R<#>;F016^:)&LZA!5I@]^#E'L@TB_F;2$4-NT$[D79<A9N2HDFRW
M2[P[:GK[Q35DMQIVJ>6G>D>*HJ""HID6".%6P[.J<ZQD !G8X5B.!>+7#WAC
M<_$!:=F<+K]M6V[%O,-@6>\T>Y:2X6&R!HY!?ZF>\5]TJ:?SZ6&FFJ_9)J\-
M+-)#30J'GB1LZO$GA)R'Y=<T8B;Y$:IV= U&<N,OMC<MEO-,M51C99@&15-2
M, U?3<>P21S9Y9RSKS5A'G6\91KUR] -#2+,4,767;]TOE_22Z457'!+/)6W
M"6I@G@1T#^8\2M(BY:9RL2JAYE1BPPJ'%BO%OC;P\X0\%ZVDX=[KVO77>@LU
M'M+95LL5\M%XJJ.H>F%%2W"6"@J:@K':J.*>Y2U%3$L$]53Q02,TU6BOMW"$
M+<(F[<0P  - 0 "A(Q!").$#$(:,)0,8T)2A"$8PE"<82G&,8QCKH(
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M[J#GE9ES\<$C.LZ-S(C$8YE5L?#(!QKK7AB-FCIP$*G)0-CF$W1Y]9R"$I:
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M7*#;],2<6KJ]L39=:E'C!Z%K(O,F8Q.)>6GI3,8,CZ9:,6)VK-LZ 24=MW6
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& #L!K__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
